

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajem1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAPplus enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information
NEWS	17	DEC 21	New Indicator Identifies Multiple Basic Patent Records Containing Equivalent Chemical Indexing in CA/CAPplus

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges

and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 11:57:10 ON 09 JAN 2010

=> fil reg

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

0.22

0.22

FILE 'REGISTRY' ENTERED AT 11:57:29 ON 09 JAN 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 8 JAN 2010 HIGHEST RN 1201769-11-0

DICTIONARY FILE UPDATES: 8 JAN 2010 HIGHEST RN 1201769-11-0

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.


Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10-516,777-1.str



chain nodes :

9 10 11

ring nodes :

1 2 3 4 5 6 7 8 12 13 14 15 16 17 18 19 20

chain bonds :

9-10 10-11 10-12

ring bonds :

1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 7-8 12-13 12-16 13-14 14-15 14-17
 15-16 15-20 17-18 18-19 19-20
 exact/norm bonds :
 1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 7-8 9-10 10-11 12-13 12-16 13-14
 15-16
 exact bonds :
 10-12
 normalized bonds :
 14-15 14-17 15-20 17-18 18-19 19-20
 isolated ring systems :
 containing 12 :


Match level :
 1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
 11:CLASS 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
 20:Atom 22:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 11:57:57 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 97 TO ITERATE

100.0% PROCESSED 97 ITERATIONS

14 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1350 TO 2530


PROJECTED ANSWERS: 56 TO 504

L2 14 SEA SSS SAM L1

=> d scan

L2 14 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5,7-difluoro-
MF C16 H16 F2 N2 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 14 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro-7-(4-
fluorophenyl)-
MF C22 H20 F2 N2 O2

Absolute stereochemistry.




PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 14 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN

IN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(4-methoxyphenyl)-, hydrochloride (1:1)
MF C23 H24 N2 O3 . Cl H

Absolute stereochemistry.




● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):1

L2 14 ANSWERS REGISTRY COPYRIGHT 2010 ACS on STN
IN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
[[(methylamino)carbonyl]amino]phenyl]-, hydrochloride (1:1)
MF C24 H26 N4 O3 . Cl H

Absolute stereochemistry.



● HCl

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> s l1 sss full
FULL SEARCH INITIATED 11:58:35 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1795 TO ITERATE

100.0% PROCESSED 1795 ITERATIONS 304 ANSWERS
SEARCH TIME: 00.00.01

L3 304 SEA SSS FUL L1

=> file caplus
COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 192.03 192.25

FILE 'CAPLUS' ENTERED AT 11:58:48 ON 09 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 9 Jan 2010 VOL 152 ISS 3
FILE LAST UPDATED: 8 Jan 2010 (20100108/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.


=> s l3
L4 21 L3

=> d ibib abs hitstr 1-
YOU HAVE REQUESTED DATA FROM 21 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1500693 CAPLUS
DOCUMENT NUMBER: 152:1877
TITLE: Methods using compounds having nicotinic acetylcholine receptor activity for treating disease-induced ataxia and non-ataxic imbalance
INVENTOR(S): Zesiewicz, Theresa A.; Sullivan, Kelly L.
PATENT ASSIGNEE(S): University of South Florida, USA
SOURCE: PCT Int. Appl., 63pp.

CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009146031	A1	20091203	WO 2009-US38948	20090331
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			US 2008-41069P	P 20080331
			US 2008-41408P	P 20080401
			US 2008-43522P	P 20080409
			US 2008-56173P	P 20080527
			US 2008-76343P	P 20080627
AB	Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.			
IT	639494-67-0 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses) (TC 5619; nicotinic acetylcholine receptor compds. for treatment of disease-induced ataxia and non-ataxic imbalance)			
RN	639494-67-0 CAPLUS			
CN	2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)			



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:1468018 CAPLUS
DOCUMENT NUMBER: 152:1868
TITLE: Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity
INVENTOR(S): Zesiewicz, Theresa A.; Sullivan, Kelly L.; Ramsey, John Edward
PATENT ASSIGNEE(S): University of South Florida, USA

SOURCE: PCT Int. Appl., 54pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009143019	A2	20091126	WO 2009-US44155	20090515
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2008-55692P P 20080523


AB Methods for treatment of peripheral nerve sensory loss are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity. Two patients with atypical Friedreich ataxia experienced modest proprioceptive improvements in their extremities within a month of taking varenicline, a drug approved for smoking cessation.

IT 639494-67-0, TC 5619

RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(as compound having nicotinic acetylcholine receptor activity; peripheral nerve sensory loss treatment using compds. having nicotinic acetylcholine receptor activity)

RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



L4 ANSWER 3 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1168740 CAPLUS

DOCUMENT NUMBER: 151:373961

TITLE: Method and compositions using $\alpha 7$ nicotinic acetylcholine receptor modulators for treatment of inflammatory disorders, including cerebral malaria

INVENTOR(S): Bencherif, Merouane

PATENT ASSIGNEE(S): USA

SOURCE: U.S. Pat. Appl. Publ., 11pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090239901	A1	20090924	US 2009-407010	20090319
PRIORITY APPLN. INFO.:			US 2008-37860P	P 20080319

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT


AB The invention discloses a method for treating inflammatory disorders, including cerebral malaria, by administration of modulators of $\alpha 7$ nicotinic acetylcholine receptor.

IT 639489-84-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 ($\alpha 7$ nicotinic acetylcholine receptor modulators for treatment of inflammatory disorders, including cerebral malaria)

RN 639489-84-2 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1072275 CAPLUS

DOCUMENT NUMBER: 151:280270

TITLE: Compositions for treatment of cognitive disorders

INVENTOR(S): Rueter, Lynne E.; Fox, Gerald B.; Browman, Kaitlin E.; Sullivan, James P.; Brioni, Jorge D.; Cowart, Marlon D.; Faghih, Ramin; Gfesser, Gregory A.; Mortell, Kathleen H.; Gopalakrishnan, Murali

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: U.S. Pat. Appl. Publ., 33pp.; Chemical Indexing Equivalent to 151:116642 (WO)
 CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090221648	A1	20090903	US 2008-338865	20081218
WO 2009082698	A1	20090702	WO 2008-US87729	20081219

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,

CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
 FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
 KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
 ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: US 2007-15996P P 20071221
 US 2007-17388P P 20071228
 US 2008-338849 A 20081218
 US 2008-338865 A 20081218


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to compns. for treatment of cognitive deficits. Such compns. can have a nicotinic acetylcholine receptor ligand, of either $\alpha 4\beta 2$ subtype or $\alpha 7$ nicotinic acetylcholine subtype, and a histamine-3 receptor ligand, a method of using the same, and a related article of manufacture Combinations of such active agents with psychostimulants or monoamine reuptake inhibitors also is contemplated.

IT 639494-67-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. for combination therapy of cognitive diseases)

RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



L4 ANSWER 5 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1017144 CAPLUS

DOCUMENT NUMBER: 151:272947

TITLE: Combination of $\alpha 7$ -nicotinic agonists and antipsychotics for treatment of psychiatric disorders

INVENTOR(S): Bencherif, Merouane; Gatto, Gregory J.; Hauser, Terry; Jordan, Kristen G.; Letchworth, Sharon R.

PATENT ASSIGNEE(S): Targacept, Inc., USA

SOURCE: PCT Int. Appl., 94pp.
 CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009102962	A2	20090820	WO 2009-US34062	20090213

WO 2009102962 A3 20091008

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: US 2008-28282P P 20080213

OTHER SOURCE(S): MARPAT 151:272947

AB The present invention relates to a synergistic combination of an $\alpha 7$ -nicotinic agonist and an antipsychotic agent, to pharmaceutical compns. and kits comprising such a combination and to methods for treatment or prevention of psychiatric disorders, particularly psychotic disorders, by administering said combination. Thus, a pharmaceutical composition was prepared by combining an $\alpha 7$ -nicotinic agonist (2S,3R)-N-[2-[(3-pyridinyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl]benzofuran-2-carboxamide (Compound A) with an atypical antipsychotic drug clozapine in a pharmaceutically-acceptable carrier in amts. that deliver a therapeutically-effective amount of each drug. Clozapine (3.0 mg/kg) and Compound A (0.1 mg/kg), when given individually to transgenic th(tk)/th(tk) mice, a model of human schizophrenia, had little effect on prepulse inhibition (PPI) or startle. In contrast, there was a significant main effect of clozapine plus Compound A. No synergistic effects were observed in control mice.

IT 639489-84-2 639494-67-0 1111941-88-8
1111941-89-9 1111941-90-2 1111942-11-0
1181294-24-5 1181294-25-6 1181294-26-7
1181294-27-8 1181294-28-9 1181294-29-0
1181294-30-3 1181294-31-4


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(compns. comprising $\alpha 7$ -nicotinic agonists and antipsychotics for treatment or prevention of psychiatric disorders)

RN 639489-84-2 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-

yl]- (CA INDEX NAME)



RN 1111941-88-8 CAPLUS


CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P



RN 1111941-89-9 CAPLUS


CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2


CRN 110-16-7
CMF C4 H4 O4

Double bond geometry as shown.



RN 1111941-90-2 CAPLUS
CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


RN 1111942-11-0 CAPLUS
CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2


CRN 104-15-4

CMF C7 H8 O3 S




RN 1181294-24-5 CAPLUS

CN 2-Benzofurancarboxamide, 3-methyl-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-25-6 CAPLUS

CN 2-Benzofurancarboxamide, 5-nitro-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-26-7 CAPLUS

CN 2-Benzofurancarboxamide, 5-methoxy-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-27-8 CAPLUS

CN 2-Benzofurancarboxamide, 7-methoxy-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-28-9 CAPLUS

CN 2-Benzofurancarboxamide, 7-ethoxy-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-29-0 CAPLUS

CN 2-Benzofurancarboxamide, 5-chloro-3-methyl-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-30-3 CAPLUS

CN 2-Benzofurancarboxamide, 6-bromo-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



RN 1181294-31-4 CAPLUS

CN 2-Benzofurancarboxamide, 4-acetyl-7-methoxy-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



L4 ANSWER 6 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1005288 CAPLUS

DOCUMENT NUMBER: 151:440493

TITLE: TC-5619: An $\alpha 7$ neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia

AUTHOR(S): Hauser, T. A.; Kucinski, A.; Jordan, K. G.; Gatto, G. J.; Wersinger, S. R.; Hesse, R. A.; Stachowiak, E. K.; Stachowiak, M. K.; Papke, R. L.; Lippiello, P. M.; Bencherif, M.

CORPORATE SOURCE: Preclinical Research, Targacept, Inc., Winston-Salem, NC, 27101, USA

SOURCE: Biochemical Pharmacology (2009), 78(7), 803-812
CODEN: BCPCA6; ISSN: 0006-2952

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A growing body of evidence suggests that the $\alpha 7$ neuronal nicotinic receptor (NNR) subtype is an important target for the development of novel therapies to treat schizophrenia, offering the possibility to address not only the pos. but also the cognitive and neg. symptoms associated with the disease. In order to probe the relationship of $\alpha 7$ function to relevant behavioral correlates we employed TC-5619, a novel selective agonist for the $\alpha 7$ NNR subtype. TC-5619 binds with very high affinity to the $\alpha 7$ subtype and is a potent full agonist. TC-5619 has little or no activity at other nicotinic receptors, including the $\alpha 4\beta 2$, ganglionic ($\alpha 3\beta 4$) and muscle subtypes. The transgenic th(tk-)/th(tk-) mouse model that reflects many of the developmental, anatomical, and multi-transmitter biochem. aspects of schizophrenia was used to assess the antipsychotic effects of TC-5619. In these mice TC-5619 acted both alone and synergistically with the antipsychotic clozapine to correct impaired pre-pulse inhibition (PPI) and social behavior which model pos. and neg. symptoms, resp. Antipsychotic and cognitive effects of TC-5619 were also assessed in rats. Similar to the results in the transgenic mice, TC-5619 significantly reversed apomorphine-induced PPI deficits. In a novel object recognition paradigm in rats TC-5619 demonstrated long-lasting enhancement of memory over a wide dose range. These results suggest that $\alpha 7$ -selective agonists such as TC-5619, either alone or in combination with antipsychotics, could offer a new approach to treating the constellation of symptoms associated with schizophrenia, including cognitive dysfunction.


IT 639494-67-0, TC 5619

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(TC 5619; effect of alpha7 neuronal nicotinic receptor-selective agonist TC-5619 in animal model of pos. and neg. symptoms and cognitive dysfunction of schizophrenia)

RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:827050 CAPLUS

DOCUMENT NUMBER: 151:132241

TITLE: Transdermal therapeutic system having a content of a modulator for nicotinic acetylcholine receptors (nAChR)

INVENTOR(S): Meyer, Elisabeth; Tisa-Bostedt, Katalin; Beckert, Thomas

PATENT ASSIGNEE(S): Acino A.-G., Germany

SOURCE: Ger. Offen., 12pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102007058504	A1	20090709	DE 2007-102007058504	20071205
WO 2009071326	A2	20090611	WO 2008-EP10380	20081205
WO 2009071326	A3	20091001		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW

RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: DE 2007-102007058504A 20071205

AB The invention relates to a transdermal therapeutic system (TTS) having a content of at least one modulator for nicotinic acetylcholine receptors (nAChR modulator). Thus a matrix was prepared by dissolving 5-15 weight% epibatidine in ethylmethylketone (1: 4.2); 0.1-20 weight% Aloe vera extract was

added as penetration enhancer along with Durotak DT-6173. The homogenized mixture was applied onto a polyester foil, dried and covered with a siliconized foil.

IT 634904-39-5


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ABBF; transdermal therapeutic system having a content of a modulator for nicotinic acetylcholine receptors (nAChR))

RN 634904-39-5 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 639494-67-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(transdermal therapeutic system having a content of a modulator for nicotinic acetylcholine receptors (nAChR))

RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



REFERENCE COUNT:

6

THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:796430 CAPLUS


DOCUMENT NUMBER: 151:116642

TITLE: Compositions containing a nicotinic $\alpha 7$ subunit or a nicotinic $\alpha 4\beta 2$ receptor ligand and a histamine-3 receptor ligand for treatment of cognitive disorders

INVENTOR(S): Rueter, Lynne E.; Fox, Gerard B.; Browman, Kaitlin E.;

Sullivan, James P.; Brioni, Jorge D.; Cowart, Marlon D.; Faghih, Ramin; Gfesser, Gregory A.; Mortell, Kathleen H.; Gopalakrishnan, Murali
PATENT ASSIGNEE(S): Abbott Laboratories, USA
SOURCE: PCT Int. Appl., 96pp.; Chemical Indexing Equivalent to 151:280270 (US)
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009082698	A1	20090702	WO 2008-US87729	20081219
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
US 20090163470	A1	20090625	US 2008-338849	20081218
US 20090221648	A1	20090903	US 2008-338865	20081218
PRIORITY APPLN. INFO.:			US 2007-15996P	P 20071221
			US 2007-17388P	P 20071228
			US 2008-338849	A 20081218
			US 2008-338865	A 20081218
OTHER SOURCE(S):			MARPAT 151:116642	
GI				



AB The invention is related to compns. containing a nicotinic $\alpha 7$ subunit of formula I [R1 = H, Me, Ph, pyrazolyl, OH; R2 = OH, :CH2, :CHRC, (un)substituted alk(en)yl; Rc = alkyl, halo; R3 = (un)substituted (hetero)aryl, G1-L-G2; G1 = (hetero)arylene; L = a bond, O, alkylene, alkoxyline; G2 = (hetero)aryl, cycloalkyl, heterocyclyl; R4 = (un)substituted cyclo/alkyl, heteroaryl, heterocyclyl, NH2 and derivs. with provisos] or a nicotinic $\alpha 4\beta 2$ receptor ligand and a histamine-3 receptor ligand for treatment of cognitive deficits. The invention is also related to combinations of such active agents with psychostimulants or monoamine reuptake inhibitors. The $\alpha 7$ ligand 2-methyl-5-(6-phenylpyridazin-3-yl)octahydropyrrolo[3,4-c]pyrrole induced

a significant, dose dependent effect, with the dose of 1 μ mol/kg increasing transfer latency, while the reuptake inhibitor atomoxetine did not alter the transfer latency, demonstrating that adding treatment with an $\alpha 7$ receptor ligand to treatment with reuptake inhibitors will result in greater clin. efficacy than that seen with reuptake inhibitors alone.

IT 639494-67-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (pharmaceutical compns. for combination therapy of cognitive diseases)
 RN 639494-67-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:708100 CAPLUS

DOCUMENT NUMBER: 151:42043

TITLE: Transdermal therapeutic system having a content of a modulator for nicotinic acetylcholine receptors (nAChR)

INVENTOR(S): Meyer, Elisabeth; Tisa-Bostedt, Katalin; Beckert, Thomas

PATENT ASSIGNEE(S): Acino A.-G., Germany

SOURCE: PCT Int. Appl., 30 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009071326	A2	20090611	WO 2008-EP10380	20081205
WO 2009071326	A3	20091001		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
DE 102007058504	A1	20090709	DE 2007-102007058504	20071205

PRIORITY APPLN. INFO.:

DE 2007-102007058504A 20071205

AB The invention relates to a transdermal therapeutic system (TTS) having a content of at least one modulator for nicotinic acetylcholine receptors (nAChR modulator). Thus a matrix was prepared by dissolving 5-15 weight% epibatidine in ethylmethylketone (1: 4.2); 0.1-20 weight% Aloe vera extract was added as penetration enhancer along with Durotak DT-6173. The homogenized mixture was applied onto a polyester foil, dried and covered with a siliconized foil.

IT 634904-39-5


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(ABBF; transdermal therapeutic system having a content of a modulator for nicotinic acetylcholine receptors (nAChR))

RN 634904-39-5 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.




IT 639494-67-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(transdermal therapeutic system having a content of a modulator for nicotinic acetylcholine receptors (nAChR))

RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



L4 ANSWER 10 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:143404 CAPLUS

DOCUMENT NUMBER: 150:206370

TITLE: Treatment with $\alpha 7$ nAChR-selective ligands

INVENTOR(S): Bencherif, Merouane; Marrero, Mario B.

PATENT ASSIGNEE(S): Targacept, Inc., USA; Medical College of Georgia
 SOURCE: PCT Int. Appl., 103pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009018511	A2	20090205	WO 2008-US71893	20080801
WO 2009018511	A3	20090423		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20090048290	A1	20090219	US 2008-184312	20080801
PRIORITY APPLN. INFO.:			US 2007-953610P	P 20070802
			US 2007-953613P	P 20070802
			US 2007-953614P	P 20070802
			US 2007-971654P	P 20070912

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention includes methods, uses, and selective $\alpha 7$ nAChR agonist compds. for treating or preventing metabolic disorders.


IT 639489-84-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (treatment with $\alpha 7$ nAChR-selective agonists)

RN 639489-84-2 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




IT 1111941-90-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(treatment with $\alpha 7$ nAChR-selective agonists)
 RN 1111941-90-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 1111942-11-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (treatment with $\alpha 7$ nAChR-selective agonists)
 RN 1111942-11-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2
 CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2


CRN 104-15-4

CMF C7 H8 O3 S



IT 639489-82-0P
RL: SPN (Synthetic preparation); PREP (Preparation)
(treatment with $\alpha 7$ nAChR-selective agonists)
RN 639489-82-0 CAPLUS
CN 2-Benzofurancarboxamide, N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2009:138975 CAPLUS
DOCUMENT NUMBER: 150:214178
TITLE: Preparation of
(2S,3R)-N-[2-(3-pyridylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzofuran-2-carboxamide and salts as neuronal nicotinic receptor $\alpha 7$ ligands.
INVENTOR(S): Bencherif, Merouane; Benson, Lisa; Dull, Gary Maurice; Fedorov, Nikolai; Gatto, Gregory J.; Genus, John; Jordan, Kristen G.; Mathew, Jacob; Mazurov, Anatoly A.; Miao, Lan; Munoz, Julio A.; Pfeiffer, Inigo; Pfeiffer, Sondra; Phillips, Teresa Y.
PATENT ASSIGNEE(S): Targacept, Inc., USA
SOURCE: PCT Int. Appl., 81pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009018505	A1	20090205	WO 2008-US71872	20080801
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,			

ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
 PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
 TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20090048290 A1 20090219 US 2008-184312 20080801
 PRIORITY APPLN. INFO.: US 2007-953610P P 20070802
 US 2007-953613P P 20070802
 US 2007-953614P P 20070802
 US 2007-971654P P 20070912


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB (2S,3R)-N-[2-(3-pyridylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzofuran-2-
 carboxamide (I) and salts were prepared Thus,
 (2S,3R)-3-amino-2-(3-pyridylmethyl)-1-azabicyclo[2.2.2]octane (preparation
 given), benzofuran-2-carboxylic acid, Et3N, and HBTU were stirred 4 h in
 CH2Cl2 to give 77% I. I competitively inhibits binding of radiolabeled
 MMA to rat brain hippocampus $\alpha 7$ NNRs with $K_i = 1$ nM.
 IT 1111942-11-0P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide
 and salts as neuronal nicotinic receptor $\alpha 7$ ligands)
 RN 1111942-11-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-
 azabicyclo[2.2.2]oct-3-yl]-, 4-methylbenzenesulfonate (1:1) (CA INDEX
 NAME)

CM 1


CRN 639489-84-2
 CMF C22 H23 N3 O2

Absolute stereochemistry.




CM 2

CRN 104-15-4
 CMF C7 H8 O3 S



IT 1111941-90-2P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide and salts as neuronal nicotinic receptor $\alpha 7$ ligands)
 RN 1111941-90-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 639489-84-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide and salts as neuronal nicotinic receptor $\alpha 7$ ligands)
 RN 639489-84-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 1111941-88-8P 1111941-89-9P 1111941-91-3P
 1111941-93-5P 1111941-94-6P 1111941-95-7P
 1111941-96-8P 1111941-97-9P 1111941-98-0P
 1111941-99-1P 1111942-00-7P 1111942-01-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide
 and salts as neuronal nicotinic receptor $\alpha 7$ ligands)

RN 1111941-88-8 CAPLUS


CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-
 azabicyclo[2.2.2]oct-3-yl]-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2


CRN 7664-38-2

CMF H3 O4 P




RN 1111941-89-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)
 CM 1
 CRN 639489-84-2
 CMF C22 H23 N3 O2

Absolute stereochemistry.




CM 2
 CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RN 1111941-91-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 1111941-93-5 CAPLUS
 CN Galactaric acid, compd. with N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-2-benzofurancarboxamide (1:2) (CA INDEX NAME)

CM 1

CRN 639489-84-2
 CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 526-99-8
 CMF C6 H10 O8

Relative stereochemistry.




RN 1111941-94-6 CAPLUS
CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2
CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 147-71-7
CMF C4 H6 O6

Absolute stereochemistry.




RN 1111941-95-7 CAPLUS
CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2
CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 1111941-96-8 CAPLUS


CN Benzeneacetic acid, α -hydroxy-, (α R)-, compd. with
N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-2-
benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2

Absolute stereochemistry.




CM 2

CRN 611-71-2

CMF C8 H8 O3

Absolute stereochemistry. Rotation (-).




RN 1111941-97-9 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,
(1R,4S)-, compd. with N-[(2S,3R)-2-(3-pyridinylmethyl)-1-
azabicyclo[2.2.2]oct-3-yl]-2-benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2
CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 35963-20-3
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (-).




RN 1111941-98-0 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,
(1S,4R)-, compd. with N-[(2S,3R)-2-(3-pyridinylmethyl)-1-
azabicyclo[2.2.2]oct-3-yl]-2-benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2

Absolute stereochemistry.




CM 2

CRN 3144-16-9

CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



RN 1111941-99-1 CAPLUS


CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 1111942-00-7 CAPLUS


CN Pentanedioic acid, 2-oxo-, compd. with
N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-2-
benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 328-50-7

CMF C5 H6 O5



RN 1111942-01-8 CAPLUS


CN Glycine, N-benzoyl-, compd. with N-[(2S,3R)-2-(3-pyridinylmethyl)-1-
azabicyclo[2.2.2]oct-3-yl]-2-benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 495-69-2

CMF C9 H9 N O3



IT 1111942-04-1P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide
and salts as neuronal nicotinic receptor $\alpha 7$ ligands)

RN 1111942-04-1 CAPLUS


CN Benzoic acid, 4-chloro-, compd. with
N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-2-
benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-80-8

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2


CRN 74-11-3

CMF C7 H5 Cl O2




IT 639489-80-8P 639489-86-4P 1111942-02-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide
and salts as neuronal nicotinic receptor $\alpha 7$ ligands)
RN 639489-80-8 CAPLUS
CN 2-Benzofurancarboxamide, N-[(2R,3R)-2-(3-pyridinylmethyl)-1-
azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 639489-86-4 CAPLUS
CN 2-Benzofurancarboxamide, N-[(2S,3S)-2-(3-pyridinylmethyl)-1-
azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1111942-02-9 CAPLUS
CN Galactaric acid, compd. with N-[(2R,3R)-2-(3-pyridinylmethyl)-1-
azabicyclo[2.2.2]oct-3-yl]-2-benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-80-8

CMF C22 H23 N3 O2

Absolute stereochemistry.




CM 2

CRN 526-99-8

CMF C6 H10 O8

Relative stereochemistry.



IT 639489-82-0P 1111942-03-0P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide and salts as neuronal nicotinic receptor $\alpha 7$ ligands)

RN 639489-82-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1111942-03-0 CAPLUS
 CN Galactaric acid, compd. with N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-2-benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-86-4
 CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 526-99-8
 CMF C6 H10 O8

Relative stereochemistry.



OS.CITING REF COUNT:	1	THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT:	2	THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:513292 CAPLUS

DOCUMENT NUMBER: 147:109919

TITLE: The novel $\alpha 7$ nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents

AUTHOR(S): Boess, Frank G.; De Vry, Jean; Erb, Christina; Flessner, Timo; Hendrix, Martin; Luithle, Joachim; Methfessel, Christoph; Riedl, Bernd; Schnizler, Katrin; van der Staay, Franz-Josef; van Kampen, Marja; Wiese, Welf Burkhard; Koenig, Gerhard

CORPORATE SOURCE: Pharma Research CNS, Bayer HealthCare AG, Wuppertal, Germany

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2007), 321(2), 716-725

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The relative contribution of $\alpha 4\beta 2$, $\alpha 7$ and other nicotinic acetylcholine receptor (nAChR) subtypes to the memory enhancing vs. the addictive effects of nicotine is the subject of ongoing debate. In the present study, we characterized the pharmacol. and behavioral properties of the $\alpha 7$ nAChR agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide (ABBF). ABBF bound to $\alpha 7$ nAChR in rat brain membranes ($K_i = 62$ nM) and to recombinant human 5-hydroxytryptamine (5-HT)₃ receptors ($K_i = 60$ nM). ABBF was a potent agonist at the recombinant rat and human $\alpha 7$ nAChR expressed in *Xenopus* oocytes, but it did not show agonist activity at other nAChR subtypes. ABBF acted as an antagonist of the 5-HT₃ receptor and $\alpha 3\beta 4$, $\alpha 4\beta 2$, and muscle nAChRs (at higher concns.). ABBF improved social recognition memory in rats (0.3-1 mg/kg p.o.). This improvement was blocked by intracerebroventricular administration of the $\alpha 7$ nAChR antagonist methyllycaconitine at 10 μ g, indicating that it is mediated by $\alpha 7$ nAChR agonism. In addition, ABBF improved working memory of aged rats in a water maze repeated acquisition paradigm (1 mg/kg p.o.) and object recognition memory in mice (0.3-1 mg/kg p.o.). Rats trained to discriminate nicotine (0.4 mg/kg s.c.) from vehicle did not generalize to ABBF (0.3-30 mg/kg p.o.), suggesting that the nicotine cue is not mediated by the $\alpha 7$ nAChR and that selective $\alpha 7$ nAChR agonists may not share the abuse liability of nicotine. Our results support the hypothesis that $\alpha 7$ nAChR agonists may provide a novel therapeutic strategy for the treatment of cognitive deficits with low abuse potential.

IT 634904-11-3


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

($\alpha 7$ nicotinic acetylcholine receptor agonist
[azabicyclooctyl][(methoxy)phenyl]benzofurancarboxamide improves memory with low abuse potential in rodents)

RN 634904-11-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

OS.CITING REF COUNT: 35 THERE ARE 35 CAPLUS RECORDS THAT CITE THIS
RECORD (35 CITINGS)
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:228801 CAPLUS
DOCUMENT NUMBER: 146:462113
TITLE: Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective α_2C -adrenergic receptor antagonists
AUTHOR(S): Hagiwara, Koji; Kashima, Hajime; Iida, Kyoichiro; Enokizono, Junichi; Uchida, Shin-ichi; Nonaka, Hiromi; Kurokawa, Masako; Shimada, Junichi
CORPORATE SOURCE: Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd, 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8731, Japan
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(6), 1616-1621
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:462113
GI



AB The synthesis of a series of 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-2-arylbenzofuran and 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran-2-carboxamide derivs. as novel α_2 C-adrenergic receptor antagonists are described. Their affinity at three different human α_2 -adrenergic receptors is reported, and some of these compds. exhibited high affinity for the α_2 C-adrenergic receptor with high subtype selectivity. Among them, the monofumarate of compound I has been found to show the anti-L-dopa-induced dyskinetic activity in marmosets. The structure-activity relationship of these compds. is also discussed.

IT 934969-56-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)
(preparation of 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivs. as selective α_2 C-adrenergic receptor antagonists)

RN 934969-56-9 CAPLUS


CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-7-methoxy-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 934969-55-8

CMF C29 H35 N3 O5

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:1313798 CAPLUS

DOCUMENT NUMBER: 146:454924

TITLE: Therapeutic potential of novel selective drugs in targeting nicotinic acetylcholine receptors

AUTHOR(S): Bencherif, Merouane; Hauser, Terry A.; Jordan, Kristen G.; Gatto, Gregory J.

CORPORATE SOURCE: Preclinical Research, Targacept, Inc., Winston-Salem, NC, 27101, USA

SOURCE: Journal of Molecular Neuroscience (2006), 30(1-2), 17-18

CODEN: JMNEES; ISSN: 0895-8696

PUBLISHER: Humana Press Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Investigation of $\alpha 7$ functional activity showed a full range of activities from antagonists to full agonists without any significant activity at the human 5-HT₃ receptor, P 450 isoenzymes, hERG channels, or in the AMES test. Results demonstrate that potent and highly selective nAChR ligands can be designed. It is now clear that various combinations of nAChR pharmacologies can be recruited within a single mol. to optimize efficacy by targeting relevant symptomatology and minimize undesired interactions.


IT 639494-67-0, TC 5619

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic potential of novel selective drugs in targeting nicotinic receptors)

RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:980050 CAPLUS

DOCUMENT NUMBER: 145:328406

TITLE: Neuronal $\alpha 7$ nicotinic receptor ligand and antipsychotic compositions for treatment of schizophrenia

INVENTOR(S): Kohlhaas, Kathy L.; Rueter, Lynne E.; Bitner, R. Scott

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: U.S. Pat. Appl. Publ., 37pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060211686	A1	20060921	US 2006-370419	20060308
CA 2601509	A1	20060928	CA 2006-2601509	20060308
WO 2006101745	A2	20060928	WO 2006-US8289	20060308
WO 2006101745	A3	20070125		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1863485	A2	20071212	EP 2006-737458	20060308
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008533142	T	20080821	JP 2008-501915	20060308
MX 2007011436	A	20071012	MX 2007-11436	20070917
PRIORITY APPLN. INFO.:			US 2005-663184P	P 20050318
			WO 2006-US8289	W 20060308


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 145:328406

AB The present invention relates to a composition comprising an antipsychotic agent and a neuronal $\alpha 7$ nicotinic acetylcholine receptor ligand, a method of using the same for treatment of psychotic conditions, such as schizophrenia, and a related article of manufacture. The neuronal $\alpha 7$ nicotinic receptor ligand, i.e., a nicotinic agonist, a nicotinic partial agonist, or a nicotinic allosteric modulator is selected from diazabicycloalkane derivs., spirocyclic quinuclidinic ether derivs., bicycloheterocycle-substituted quinuclidine derivs., 3-quinuclidinyl amino-substituted biaryl derivs., 3-quinuclidinyl heteroatom-bridged biaryl derivs., and amino-substituted tricyclic derivs. Thus, nicotinic $\alpha 7$ receptor agonist 5-(6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl)-1H-indole (Compound 1) potentiated antipsychotic effect of sub-efficacious dose of risperidone in mouse model of schizophrenia. Compound 1 alone at 0.04 mg/kg did not have an effect, but when combined with a sub-efficacious dose of risperidone (0.1 mg/kg), a maximally efficacious response was achieved. Such a response was similar to that achieved by a 10-fold higher dose of risperidone (1.0 mg/kg). The

results demonstrated that a dose that was normally weakly efficacious could be made to exhibit robust efficacy upon $\alpha 7$ receptor activation by an agonist. The plasma concentration of Compound 1 required to achieve this effect was less than 100 nM.

IT 639494-67-0, TC 5619
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compsns. comprising antipsychotic and neuronal $\alpha 7$ nicotinic receptor ligand for treatment of schizophrenia and related disorders)
 RN 639494-67-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L4 ANSWER 16 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:979654 CAPLUS

DOCUMENT NUMBER: 143:266925

TITLE: Preparation of imidazo[4,5-b]pyridine derivatives as GPR4 receptor antagonists

INVENTOR(S): Iida, Kyoichiro; Otsubo, Nobumasa; Kuboyama, Takeshi; Arai, Hitoshi; Watanabe, Akihiko; Saki, Mayumi; Hiura, Naoko; Manabe, Haruhiko; Takada, Hidenori; Saito, Jun

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 215 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082905	A1	20050909	WO 2005-JP3687	20050225
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2004-50933 A 20040226
 JP 2004-307947 A 20041022

OTHER SOURCE(S): MARPAT 143:266925

GI



AB The title compds. I [wherein R1 = H, halo, NH2, etc.; R2-R4 = independently H, halo, CN, etc.; Y = N or (un)substituted CH; X = (un)substituted NH; Z1-Z4 = independently N or (un)substituted CH; W = NO2, CHO, (un)substituted alkyl, etc.] or pharmaceutically acceptable salts thereof are prepared as G protein-coupled receptor (GPR4) antagonists for the treatment of neutrophil inflammation. For example, the compound II was prepared in a multi-step synthesis. II inhibited 98% of human GPR4 at the concentration of 1 μ M.


IT 863876-47-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazo[4,5-b]pyridine derivs. as GPR4 receptor antagonists)

RN 863876-47-5 CAPLUS

CN 2-Benzofurancarboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-5-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-7-methoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:286359 CAPLUS

DOCUMENT NUMBER: 143:19236

TITLE: 2-(Arylmethyl)-3-substituted quinuclidines as selective α 7 nicotinic receptor ligands

AUTHOR(S): Mazurov, Anatoly; Klucik, Jozef; Miao, Lan; Phillips, Teresa Y.; Seamans, Angela; Schmitt, Jeffrey D.; Hauser, Terry A.; Johnson, Raymond T.; Miller, Craig
 CORPORATE SOURCE: Medicinal Chemistry, Targacept, Inc., Winston-Salem, NC, 27101, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(8), 2073-2077
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:19236


AB A series of 2-(arylmethyl)-3-substituted quinuclidines was developed as $\alpha 7$ neuronal nicotinic acetylcholine receptor (nAChR) agonists based on a putative pharmacophore model. The series is highly selective for the $\alpha 7$ over other nAChRs (e.g., the $\alpha 4\beta 2$ of the CNS, and the muscle and ganglionic subtypes) and is functionally tunable at $\alpha 7$. One member of the series, (+)-N-(1-azabicyclo[2.2.2]oct-3-yl)benzo[b]furan-2-carboxamide, has potent agonistic activity for the $\alpha 7$ nAChR (EC₅₀ = 33 nM, I_{max} = 1.0), at concns. below those that result in desensitization.

IT 852476-47-2P 852476-66-5P 852812-62-5P
 852812-63-6P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (arylmethyl-substituted quinuclidines as selective $\alpha 7$ nicotinic receptor ligands)

RN 852476-47-2 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 852476-66-5 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 852812-62-5 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 852812-63-6 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



OS.CITING REF COUNT: 10

THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 34

THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:117115 CAPLUS

DOCUMENT NUMBER: 140:181328

TITLE: Preparation of benzothiophenes, benzofuranes and indoles for improvement of cognition, attention achievement, learning achievement and/or memory achievement

INVENTOR(S): Flessner, Timo; Boess, Frank-Gerhard; Erb, Christina; Hafner, Frank-Thorsten; Schnizler, Katrin; Lang, Dieter; Luithle, Joachim; Van Kampen, Marja; Van der Staay, Franz-Josef

PATENT ASSIGNEE(S): Bayer AG, Germany

SOURCE: Ger. Offen., 35 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10234424	A1	20040212	DE 2002-10234424	20020729
CA 2494352	A1	20040212	CA 2003-2494352	20030714
WO 2004013136	A1	20040212	WO 2003-EP7588	20030714
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003254343	A1	20040223	AU 2003-254343	20030714
EP 1527073	A1	20050504	EP 2003-766162	20030714
EP 1527073	B1	20070822		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2005538111	T	20051215	JP 2004-525191	20030714
ES 2291694	T3	20080301	ES 2003-766162	20030714
US 20060106096	A1	20060518	US 2005-522611	20051215
PRIORITY APPLN. INFO.:			DE 2002-10234424	A 20020729
			WO 2003-EP7588	W 20030714

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:181328

GI



AB Title compds. [I; R1 = 1-azabicyclo[2.2.2]oct-3-yl; R2 = H, alkyl; R3 = H,

halo, amino, OH, C1-6 alkyl; R4 = H, (substituted) C1-6 alkyl; R5 = H, C1-6 alkyl; or R4R5 = (substituted) 5-6 membered heterocyclyl; R6 = H, alkyl, cycloalkyl, aryl, (substituted) 5-6 membered heterocyclyl, etc.; NR5R6 = (substituted) 3-8 membered heterocyclyl; A = O, N, S; X = O, S; B = (substituted) benzo or pyrido ring], were prepared Thus, 6-amino-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamide dihydrochloride (preparation given) in THF was reacted with Et3N and 2,6-difluorophenyl isocyanate for 18 h at room temperature to give 75.9% N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-[(2,6-difluorophenyl)aminocarbonylamino]-1-benzothiophene-2-carboxamide hydrochloride. The latter showed affinity to $\alpha 7$ -NACHR by inhibiting [3H]methyllycaconite binding in rat brain membranes with $K_i = 0.4$ nM.

IT 657401-46-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzothiophenes, benzofuranes and indoles for improvement of cognition, attention achievement, learning achievement and/or memory achievement)

RN 657401-46-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[[[(4-methoxyphenyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 550999-21-8P 550999-22-9P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of benzothiophenes, benzofuranes and indoles for improvement of cognition, attention achievement, learning achievement and/or memory achievement)

RN 550999-21-8 CAPLUS


CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-nitro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-22-9 CAPLUS
CN 2-Benzofurancarboxamide, 6-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA
INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L4 ANSWER 19 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:3665 CAPLUS

DOCUMENT NUMBER: 140:77298

TITLE: Preparation of
3-substituted-2(arylalkyl)-1-azabicycloalkanes and
methods of treatment using these compounds

INVENTOR(S): Mazurov, Anatoly A.; Klucik, Jozef; Miao, Lan;
Seamans, Angela S.; Phillips, Teresa Youngpeter;
Schmitt, Jeffrey Daniel; Miller, Craig Harrison

PATENT ASSIGNEE(S): Targacept, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S.
Ser. No. 162,129.
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
US 20040002513	A1	20040101	US 2003-372642	20030221
US 6953855	B2	20051011		
US 6432975	B1	20020813	US 1998-210113	19981211
US 20030045523	A1	20030306	US 2002-162129	20020604
AU 2004215386	A1	20040910	AU 2004-215386	20040220
AU 2004215386	B2	20090611		
CA 2514135	A1	20040910	CA 2004-2514135	20040220
WO 2004076449	A2	20040910	WO 2004-US5044	20040220
WO 2004076449	A3	20041216		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI			
RW:	BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
EP 1594869	A2	20051116	EP 2004-713356	20040220
EP 1594869	B1	20071219		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
BR 2004007708	A	20060214	BR 2004-7708	20040220
CN 1751041	A	20060322	CN 2004-80004736	20040220

JP 2006518746	T	20060817	JP 2006-503737	20040220
PT 1594869	E	20080114	PT 2004-713356	20040220
AT 381563	T	20080115	AT 2004-713356	20040220
NZ 541794	A	20080328	NZ 2004-541794	20040220
ES 2300749	T3	20080616	ES 2004-713356	20040220
CN 101220026	A	20080716	CN 2007-10159889	20040220
NZ 565177	A	20080926	NZ 2004-565177	20040220
NZ 565178	A	20090531	NZ 2004-565178	20040220
US 20050255040	A1	20051117	US 2005-157119	20050620
ZA 2005006515	A	20060628	ZA 2005-6515	20050815
KR 2006002770	A	20060109	KR 2005-715424	20050819
MX 2005008926	A	20051005	MX 2005-8926	20050822
IN 2005KN01718	A	20070323	IN 2005-KN1718	20050829
NO 2005004052	A	20051021	NO 2005-4052	20050831
HK 1083627	A1	20080613	HK 2006-105675	20060516
US 20060247270	A1	20061102	US 2006-458231	20060718
US 7425561	B2	20080916		
US 20080138287	A1	20080612	US 2008-26847	20080206
PRIORITY APPLN. INFO.:			US 1998-210113	A1 19981211
			US 2002-162129	A2 20020604
			US 2003-372642	A 20030221
			CN 2004-80004736	A3 20040220
			NZ 2004-541794	A3 20040220
			WO 2004-US5044	A 20040220
			US 2005-157119	A1 20050620
			US 2006-458231	A3 20060718


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:77298

GI



I



II

AB The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes I [A1 = (CH₂)_n; A2 = (CH₂)_m; A3 = (CH₂)_p; m, n = 1, 2; p = 1 - 4; X = O, NR'; Z = NR', covalent bond, A; A = CR'R'', CR'R''CR'R'', CR':CR', C.tplbond.C (wherein, when Z = bond or A, X = N); Ar = (un)substituted carbocyclic, heterocyclic monocyclic or fused polycyclic aryl; Cy = (un)substituted 5- or 6-membered heteroarom. ring; wavy lines = relative or absolute stereochem. (cis or trans, R or S); R', R'' = H, (un)branched C1-8-alkyl, C3-8-cycloalkyl, heterocyclyl, aryl, arylalkyl {wherein, substituents = alkyl, alkenyl, heterocyclyl, cycloalkyl, (un)substituted aryl, (un)substituted arylalkyl, F, Cl, Br, I, OR', NR'R'', CF₃, CN, NO₂, C.tplbond.CR', SR', N₃, C(:O)NR'R'', NR'C(:O)R'', C(:O)R', C(:O)OR', OC(:O)R', O(CR'R'')rC(:O)R', O(CR'R'')rNR'C(:O)R', O(CR'R'')rNR'SO₂R', OC(:O)NR'R'', NR'C(:O)OR'', SO₂R', SO₂NR'R'', NR'SO₂R''}; R'R'' = ring; r = 1 - 6] and II, methods of preparing the compds. and methods of treatment using the compds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes.

The aryl group in the arylalkyl moiety is a 5- or 6-membered ring heteroarom., preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compds. exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the $\alpha 7$ nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.


IT 639494-67-0P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-substituted-2(arylalkyl)-1-azabicycloalkanes exhibiting activity at nicotinic acetylcholine receptors)

RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



IT	639489-80-8P	639489-82-0P	639489-84-2P
	639489-86-4P	639489-96-6P	639489-98-8P
	639490-00-9P	639490-02-1P	639490-04-3P
	639490-06-5P	639490-08-7P	639490-10-1P
	639490-12-3P	639490-14-5P	639490-16-7P
	639490-18-9P	639490-21-4P	639490-23-6P
	639490-25-8P	639490-27-0P	639490-29-2P
	639490-31-6P	639490-33-8P	639490-35-0P
	639490-37-2P	639490-40-7P	639490-43-0P
	639490-45-2P	639490-47-4P	639490-49-6P
	639490-51-0P	639490-53-2P	639490-55-4P
	639490-57-6P	639490-59-8P	639490-61-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-substituted-2(arylalkyl)-1-azabicycloalkanes exhibiting activity at nicotinic acetylcholine receptors)

RN 639489-80-8 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-82-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-84-2 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-86-4 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-96-6 CAPLUS

CN 2-Benzofurancarboxamide, 3-methyl-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-98-8 CAPLUS

CN 2-Benzofurancarboxamide, 3-methyl-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-00-9 CAPLUS

CN 2-Benzofurancarboxamide, 3-methyl-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-02-1 CAPLUS

CN 2-Benzofurancarboxamide, 3-methyl-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-04-3 CAPLUS

CN 2-Benzofurancarboxamide, 5-nitro-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-06-5 CAPLUS

CN 2-Benzofurancarboxamide, 5-nitro-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-08-7 CAPLUS

CN 2-Benzofurancarboxamide, 5-nitro-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-10-1 CAPLUS

CN 2-Benzofurancarboxamide, 5-nitro-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-12-3 CAPLUS

CN 2-Benzofurancarboxamide, 5-methoxy-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-14-5 CAPLUS

CN 2-Benzofurancarboxamide, 5-methoxy-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-16-7 CAPLUS

CN 2-Benzofurancarboxamide, 5-methoxy-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-18-9 CAPLUS

CN 2-Benzofurancarboxamide, 5-methoxy-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-21-4 CAPLUS

CN 2-Benzofurancarboxamide, 7-methoxy-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-23-6 CAPLUS

CN 2-Benzofurancarboxamide, 7-methoxy-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-25-8 CAPLUS

CN 2-Benzofurancarboxamide, 7-methoxy-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-27-0 CAPLUS

CN 2-Benzofurancarboxamide, 7-methoxy-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-29-2 CAPLUS

CN 2-Benzofurancarboxamide, 7-ethoxy-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-31-6 CAPLUS

CN 2-Benzofurancarboxamide, 7-ethoxy-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-33-8 CAPLUS

CN 2-Benzofurancarboxamide, 7-ethoxy-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-35-0 CAPLUS

CN 2-Benzofurancarboxamide, 7-ethoxy-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-37-2 CAPLUS

CN 2-Benzofurancarboxamide, 5-chloro-3-methyl-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-40-7 CAPLUS

CN 2-Benzofurancarboxamide, 5-chloro-3-methyl-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-43-0 CAPLUS

CN 2-Benzofurancarboxamide, 5-chloro-3-methyl-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-45-2 CAPLUS

CN 2-Benzofurancarboxamide, 5-chloro-3-methyl-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-47-4 CAPLUS

CN 2-Benzofurancarboxamide, 6-bromo-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-49-6 CAPLUS


CN 2-Benzofurancarboxamide, 6-bromo-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 639490-51-0 CAPLUS
CN 2-Benzofurancarboxamide, 6-bromo-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 639490-53-2 CAPLUS
CN 2-Benzofurancarboxamide, 6-bromo-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 639490-55-4 CAPLUS
CN 2-Benzofurancarboxamide, 4-acetyl-7-methoxy-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-57-6 CAPLUS

CN 2-Benzofurancarboxamide, 4-acetyl-7-methoxy-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-59-8 CAPLUS

CN 2-Benzofurancarboxamide, 4-acetyl-7-methoxy-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-61-2 CAPLUS

CN 2-Benzofurancarboxamide, 4-acetyl-7-methoxy-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD (11 CITINGS)
 REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 20 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:991508 CAPLUS

DOCUMENT NUMBER: 140:42022

TITLE: Preparation of 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of diseases effecting memory

INVENTOR(S): Luithle, Joachim; Boess, Frank-Gerhard; Erb, Christina; Hafner, Frank-Thorsten; Schnizler, Katrin; Flessner, Timo; Van Kampen, Marja; Van Der Staay, Franz-Josef

PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany




SOURCE: PCT Int. Appl., 239 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104227	A1	20031218	WO 2003-EP5735	20030602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10257078	A1	20040624	DE 2002-10257078	20021206
DE 10257537	A1	20040701	DE 2002-10257537	20021210
DE 10305922	A1	20040304	DE 2003-10305922	20030213
CA 2488761	A1	20031218	CA 2003-2488761	20030602
AU 2003238450	A1	20031222	AU 2003-238450	20030602
EP 1515967	A1	20050323	EP 2003-732517	20030602
EP 1515967	B1	20061102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012446	A	20050419	BR 2003-12446	20030602
CN 1675204	A	20050928	CN 2003-818851	20030602
JP 2005533052	T	20051104	JP 2004-511297	20030602
AT 344262	T	20061115	AT 2003-732517	20030602
ES 2276072	T3	20070616	ES 2003-732517	20030602
ZA 2004009883	A	20060222	ZA 2004-9883	20041207
MX 2004012439	A	20050419	MX 2004-12439	20041209
NO 2005000063	A	20050106	NO 2005-63	20050106
US 20060160877	A1	20060720	US 2006-516777	20060113
PRIORITY APPLN. INFO.:			DE 2002-10225536	A 20020610
			DE 2002-10257078	A 20021206
			DE 2002-10257537	A 20021210
			DE 2003-10305922	A 20030213
			WO 2003-EP5735	W 20030602
ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT				
OTHER SOURCE(S):		MARPAT 140:42022		
GI				



AB The invention relates to the novel 2-heteroaryl carboxamides I [R1 = 1-azabicyclo[2.2.2]oct-3-yl, (optionally replaced via the nitrogen atom by a group selected from the family C1-4-alkyl, benzyl and oxy); R2 = H, C1-6-alkyl; R3 = H, halogen, C1-6-alkyl; R4 = H, halogen, CN, NH2, CF3, OCF3, C1-6-alkyl, C1-6-alkylcarbonyl, C1-6-alkylamino, CHO, CO2H, C1-6-alkoxy, C1-6-alkoxycarbonyl, C1-6-alkylthio, C1-6-alkylcarbonylamino, C1-6-alkylaminocarbonyl, C1-4-alkylsulfonylamino, C3-8-cycloalkylcarbonylamino, C3-6-cycloalkylaminocarbonyl, pyrrolyl, C1-6-alkylaminocarbonyl, heterocyclcylcarbonyl, heterocyclcylcarbonylamino, heteroarylcarbonylamino, OH, Ph, heterocyclcyl; A = O, S; the ring B = benzo or pyrido (optionally replaced by the groups from the family of halogen, cyano, formyl, trifluoromethyl, trifluoromethoxy, nitro, amino, C1-6-alkyl and C1-6-alkoxy); E = C:C, aryl and heteroaryl, (wherein aryl and heteroaryl may be replaced by groups from the family of halogen, cyano, trifluoromethyl, trifluoromethoxy, nitro, amino, C1-6-alkoxy and C1-6-alkyl)] and to the solvates, salts or solvates of salts of said compds. Thus, carboxamide II was prepared from carboxamide III via coupling with 2-(HOCH2)C6H4B(OH)2 in aqueous DMF containing NaOH and catalytic [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride. The invention also relates to the use of said compds. in the production of drugs for and treatment and/or the prophylaxis of diseases for improving perception, power of concentration, learning power and/or retentiveness of memory. The affinity of I for 7 α -nicotinic acetylcholine receptor (via inhibition of [3H]Methyllycaconitine binding in rat brain membranes) was determined [Ki = 1.6 nM {I·HCl; R1 = (R)-1-azabicyclo[2.2.2]oct-3-yl, R2 = R3 = H, A = S, B = benzo; 7-ER4 = 4-(hydroxymethyl)phenyl}; Ki = <1 nM {I·2HCl; R1 = (R)-1-azabicyclo[2.2.2]oct-3-yl, R2 = R3 = H, A = S, B = benzo; 7-ER4 = 2-(aminomethyl)phenyl}; Ki = <0.1 nM {I·HCl; R1 = (R)-1-azabicyclo[2.2.2]oct-3-yl, R2 = R3 = H, A = S, B = benzo; 7-ER4 = 3-carboxyphenyl}; Ki = 3 nM {I·HCl; R1 = (R)-1-azabicyclo[2.2.2]oct-3-yl; R2 = R3 = H, A = O, B = benzo; 7-ER4 = 3-(cyclopropylaminocarbonyl)phenyl}].

IT 634904-39-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and N-oxidation or acid addition salt formation of; preparation of 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of diseases effecting memory and perception)

RN 634904-39-5 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 634904-11-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and O-demethylation, N-alkylation or free base fromation of; preparation of 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of diseases effecting memory and perception)

RN 634904-11-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 634904-58-8P 634904-62-4P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)
 (preparation and amidation of; preparation of 2-heteroaryl carboxamides for
 the treatment and/or the prophylaxis of diseases effecting memory and
 perception)
 RN 634904-58-8 CAPLUS
 CN Benzoic acid, 3-[2-[[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]-7-
 benzofuranyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-62-4 CAPLUS
 CN Benzoic acid, 3-[2-[[[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]-7-
 benzofuranyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 634904-61-3P 634904-89-5P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)

(preparation and carbamylation of; preparation of 2-heteroaryl carboxamides
for the treatment and/or the prophylaxis of diseases effecting memory and
perception)

RN 634904-61-3 CAPLUS

CN 2-Benzofurancarboxamide, 7-[2-(aminomethyl)phenyl]-N-(3R)-1-
azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 634904-89-5 CAPLUS

CN 2-Benzofurancarboxamide, 7-[2-(aminomethyl)phenyl]-N-(3S)-1-
azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 634904-23-7P 634904-41-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES


(Uses)

(preparation and carbamylation or N-acylation of; preparation of 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of diseases effecting memory and perception)

RN 634904-23-7 CAPLUS

CN 2-Benzofurancarboxamide, 7-(3-aminophenyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 634904-41-9 CAPLUS

CN 2-Benzofurancarboxamide, 7-(2-aminophenyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)

Absolute stereochemistry.



IT 550999-06-9P 550999-27-4P 550999-37-6P

634905-19-4P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation and coupling reactions of, with boronates; preparation of 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of diseases effecting memory and perception)

RN 550999-06-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-bromo-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-27-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.




RN 550999-37-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-bromo- (CA INDEX NAME)

Absolute stereochemistry.




RN 634905-19-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).



IT 550999-35-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and coupling reactions of; preparation of 2-heteroaryl
 carboxamides
 for the treatment and/or the prophylaxis of diseases effecting memory
 and perception)
 RN 550999-35-4 CAPLUS
 CN 2-Benzofuran carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo- (CA
 INDEX NAME)

Absolute stereochemistry. Rotation (+).




IT	634903-05-2P	634903-07-4P	634903-10-9P
	634903-11-0P	634903-12-1P	634903-13-2P
	634903-14-3P	634903-15-4P	634903-16-5P
	634903-17-6P	634903-18-7P	634903-88-1P
	634903-90-5P	634903-93-8P	634903-94-9P
	634903-96-1P	634903-97-2P	634903-98-3P
	634903-99-4P	634904-00-0P	634904-01-1P
	634904-02-2P	634904-03-3P	634904-06-6P
	634904-07-7P	634904-08-8P	634904-09-9P
	634904-10-2P	634904-12-4P	634904-13-5P
	634904-14-6P	634904-15-7P	634904-16-8P
	634904-17-9P	634904-18-0P	634904-19-1P
	634904-20-4P	634904-21-5P	634904-22-6P
	634904-24-8P	634904-25-9P	634904-26-0P
	634904-27-1P	634904-28-2P	634904-29-3P
	634904-30-6P	634904-31-7P	634904-32-8P
	634904-33-9P	634904-34-0P	634904-35-1P
	634904-36-2P	634904-37-3P	634904-38-4P
	634904-39-5DP, free base, salt and/or solvate		
	634904-59-9P	634904-60-2P	634904-63-5P
	634904-64-6P	634904-65-7P	634904-66-8P
	634904-67-9P	634904-68-0P	634904-69-1P
	634904-70-4P	634904-71-5P	634904-72-6P
	634904-74-8P	634904-75-9P	634904-76-0P
	634904-78-2P	634904-80-6P	634904-82-8P
	634904-84-0P	634904-85-1P	634904-87-3P
	634904-88-4P	634904-90-8P	634904-91-9P
	634904-92-0P	634904-93-1P	634904-94-2P
	634904-95-3P	634904-96-4P	634904-97-5P
	634904-98-6P	634904-99-7P	634905-00-3P
	634905-01-4P	634905-02-5P	634905-03-6P
	634905-04-7P	634905-05-8P	634905-08-1P
	634905-22-9DP, free base, salt and/or solvate		
	634905-24-1DP, free base, salt and/or solvate		
	634905-27-4DP, free base, salt and/or solvate		
	RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses) (preparation of 2-heteroaryl carboxamides for the treatment and/or the		

prophylaxis of diseases effecting memory and perception)

RN 634903-05-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[2-(hydroxymethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-07-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[3-(hydroxymethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-10-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[4-(hydroxymethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-11-0 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-12-1 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-13-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(3-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-14-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-15-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-16-5 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[4-(3-hydroxy-1-propyn-1-yl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-17-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro-7-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-18-7 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro-7-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-88-1 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-90-5 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(2-oxo-1-pyrrolidinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-93-8 CAPLUS

CN Benzoic acid, 4-[2-[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]-7-benzofuranyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-94-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(trifluoromethoxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-96-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-97-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(3-oxo-4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-98-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-99-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-00-0 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[4-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-01-1 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[4-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-02-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[3-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-03-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[4-(dimethylamino)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-06-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(4-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-07-7 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-08-8 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(4-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-09-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-10-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-12-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(4-methoxy-3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-13-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(4-morpholinylcarbonyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-14-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(1-piperidinyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 634904-15-7 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 634904-16-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [[(methylamino)carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 634904-17-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [[(ethylamino)carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 634904-18-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-19-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[[(1,1-dimethylethyl)amino]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-20-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [(methanesulfonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-21-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-
 [(cyclobutylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-22-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2-pyrimidinyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-24-8 CAPLUS

CN 2-Benzofurancarboxamide, 7-[3-(acetamido)phenyl]-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-25-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [(cyclopropylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-26-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(2-
 methoxyacetyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-27-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [(cyclobutylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-28-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-
 [(cyclopropylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-29-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[(2-methoxyacetyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-30-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-31-7 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-32-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-33-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-(4-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-34-0 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-35-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-36-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[[[(ethylamino)carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-37-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-
 [(methylamino)carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 634904-38-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[[[(1,1-
 dimethylethyl)amino]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA
 INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-39-5 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634904-59-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-60-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2,5-dimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-63-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(cyclopropylamino)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-64-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(ethylmethylamino)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-65-7 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(butylamino)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-66-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[2-methylpropyl)amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-67-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(1-piperidinylcarbonyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-68-0 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-69-1 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[[3-methoxypropyl]amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-70-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(2-methoxyethyl)methylamino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-71-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(3-ethoxypropyl)amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-72-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 634904-74-8 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(ethylmethylamino)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-75-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [(butylamino)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-76-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[2-
 methylpropyl)amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-78-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(1-piperidinylcarbonyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-80-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-82-8 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[3-methoxypropyl)amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-84-0 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[2-methoxyethyl)methylamino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-85-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(3-ethoxypropyl)amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-87-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 634904-88-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(1-pyrrolidinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-90-8 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[[[(methylamino)carbonyl]amino]methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-91-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[[[(methylamino)carbonyl]amino]methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-92-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(2,2-dimethyl-1-oxopropyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-93-1 CAPLUS
 CN 5-Isoxazolecarboxamide, N-[3-[2-[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]-7-benzofuranyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-94-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(cyclopentylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-95-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(2-methyl-1-oxopropyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-96-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(2-furanylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 634904-97-5 CAPLUS


CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 634904-39-5

CMF C23 H24 N2 O3


Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 634904-98-6 CAPLUS
CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1


CRN 634904-39-5
CMF C23 H24 N2 O3

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S




RN 634904-99-7 CAPLUS
CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 634904-39-5
CMF C23 H24 N2 O3

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 634905-00-3 CAPLUS


CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 634904-39-5

CMF C23 H24 N2 O3


Absolute stereochemistry.



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 634905-01-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-hydroxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-02-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[7-(2-methoxyphenyl)-2-benzofuranyl]carbonyl]amino]-1-methyl-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-03-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[7-(2-methoxyphenyl)-2-benzofuranyl]carbonyl]amino]-1-(phenylmethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 634905-04-7 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[7-(2-methoxyphenyl)-2-benzofuranyl]carbonyl]methylamino]-1-methyl-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 634905-05-8 CAPLUS
CN 2-Benzofurancarboxamide, 7-(2-methoxyphenyl)-N-[(3R)-1-oxido-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-08-1 CAPLUS

CN 2-Benzofurancarboxamide, 7-(5-acetyl-2-thienyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634905-22-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-24-1 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
[(cyclopropylcarbonyl)amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-27-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
[[(ethylamino)carbonyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 21 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:532663 CAPLUS

DOCUMENT NUMBER: 139:69412

TITLE: Preparation of 2-heteroarylcarboxylic acid amides for
therapeutic use as nicotinic acetylcholine receptor
agonists

INVENTOR(S): Hendrix, Martin; Boess, Frank-Gerhard; Erb, Christina;
Flessner, Timo; Van Kampen, Marja; Luithle, Joachim;
Methfessel, Christoph; Wiese, Welf Burkhard

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 164 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055878	A1	20030710	WO 2002-EP14288	20021216
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10164139	A1	20030710	DE 2001-10164139	20011227
CA 2471593	A1	20030710	CA 2002-2471593	20021216
AU 2002358718	A1	20030715	AU 2002-358718	20021216
EP 1461335	A1	20040929	EP 2002-793023	20021216
EP 1461335	B1	20070228		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
ES 2282503	T3	20071016	ES 2002-793023	20021216
US 20050119325	A1	20050602	US 2005-500096	20050111

PRIORITY APPLN. INFO.:

DE 2001-10164139

A 20011227



WO 2002-EP14288

W 20021216

OTHER SOURCE(S):

MARPAT 139:69412

GI



AB N-quinuclidinyl-2-heteroarylcarboxylic acid amides, such as I [R = 2-heteroaryl], were prepared for pharmaceutical use as nicotinic acetylcholine receptor (nAChR) agonists for the treatment of cognition, learning and memory disorders. Thus, the hydrochloride salt of amide II was prepd in 62.1% yield by an amidation reaction of 6-nitrobenzothiophene-2-carboxylic acid with (R)-3-aminoquinuclidine dihydrochloride using HATU and DIPEA in DMF. The prepared amides were assayed for $\alpha 7$ -nAChR binding activity using rat brain hippocampus tissue.

IT 550999-12-7P 550999-17-2P 550999-18-3P

550999-21-8P 550999-23-0P 550999-37-6P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of N-quinuclidinyl-2-heteroarylcarboxamides as $\alpha 7$ nicotinic acetylcholine receptor agonists for therapeutic use in the treatment of cognition, learning and memory disorders)

RN 550999-12-7 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-17-2 CAPLUS


CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 550999-18-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 550999-21-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 550999-23-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-nitro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-37-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-bromo- (CA INDEX NAME)

Absolute stereochemistry.




IT	550998-96-4P	550998-97-5P	550998-98-6P
	550999-00-3P	550999-01-4P	550999-02-5P
	550999-03-6P	550999-04-7P	550999-05-8P
	550999-06-9P	550999-07-0P	550999-08-1P
	550999-09-2P	550999-10-5P	550999-11-6P
	550999-13-8P	550999-14-9P	550999-15-0P
	550999-16-1P	550999-19-4P	550999-20-7P
	550999-22-9P	550999-24-1P	550999-25-2P
	550999-26-3P	550999-27-4P	550999-28-5P
	550999-29-6P	550999-30-9P	550999-31-0P
	550999-32-1P	550999-33-2P	550999-34-3P
	550999-35-4P	550999-36-5P	550999-41-2P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-quinuclidinyl-2-heteroarylcarboxamides as $\alpha 7$ nicotinic acetylcholine receptor agonists for therapeutic use in the treatment of cognition, learning and memory disorders)

RN 550998-96-4 CAPLUS


CN 2-Benzofurancarboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 550998-97-5 CAPLUS

CN 2-Benzofurancarboxamide, N-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)




RN 550998-98-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-,

hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-00-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-,
hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-01-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-,
(CA INDEX NAME)


Absolute stereochemistry.



RN 550999-02-5 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-,
hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-03-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5,7-dichloro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-04-7 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5,7-dichloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-05-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5,7-dichloro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-06-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-bromo-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-07-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-bromo- (CA
 INDEX NAME)

Absolute stereochemistry.



RN 550999-08-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-bromo-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-09-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-10-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-chloro- (CA
 INDEX NAME)

Absolute stereochemistry.



RN 550999-11-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-13-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-5-nitro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-14-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-15-0 CAPLUS
 CN 2-Benzofurancarboxamide, 5-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl


RN 550999-16-1 CAPLUS
 CN 2-Benzofurancarboxamide, 5-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy- (CA INDEX NAME)

Absolute stereochemistry.




RN 550999-19-4 CAPLUS
 CN 2-Benzofurancarboxamide, 5-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)

Absolute stereochemistry.




RN 550999-20-7 CAPLUS
 CN 2-Benzofurancarboxamide, 5-amino-N-(3S)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)

Absolute stereochemistry.




RN 550999-22-9 CAPLUS
CN 2-Benzofurancarboxamide, 6-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)

Absolute stereochemistry.




RN 550999-24-1 CAPLUS
CN 2-Benzofurancarboxamide, 7-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)

Absolute stereochemistry.




RN 550999-25-2 CAPLUS
CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5,7-difluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-26-3 CAPLUS
CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5,7-difluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-27-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo-5-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-28-5 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo-5-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-29-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-30-9 CAPLUS
CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-31-0 CAPLUS
CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-32-1 CAPLUS
CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-fluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-33-2 CAPLUS
CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-34-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-fluoro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-35-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo- (CA INDEX NAME)


Absolute stereochemistry. Rotation (+).



RN 550999-36-5 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-bromo-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-41-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(2-cyclopropyl-2-oxoethyl)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
 REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>
 Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:ssptajem1625

PASSWORD:
 TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAPLUS enhanced with legal status information for U.S. patents

NEWS 6 SEP 09 50 Millionth Unique Chemical Substance Recorded in
CAS REGISTRY

NEWS 7 SEP 11 WPIDS, WPINDEX, and WPIX now include Japanese FTERM
thesaurus

NEWS 8 OCT 21 Derwent World Patents Index Coverage of Indian and
Taiwanese Content Expanded

NEWS 9 OCT 21 Derwent World Patents Index enhanced with human
translated claims for Chinese Applications and
Utility Models

NEWS 10 NOV 23 Addition of SCAN format to selected STN databases

NEWS 11 NOV 23 Annual Reload of IFI Databases

NEWS 12 DEC 01 FRFULL Content and Search Enhancements

NEWS 13 DEC 01 DGENE, USGENE, and PCTGEN: new percent identity
feature for sorting BLAST answer sets

NEWS 14 DEC 02 Derwent World Patent Index: Japanese FI-TERM
thesaurus added

NEWS 15 DEC 02 PCTGEN enhanced with patent family and legal status
display data from INPADOCDB

NEWS 16 DEC 02 USGENE: Enhanced coverage of bibliographic and
sequence information

NEWS 17 DEC 21 New Indicator Identifies Multiple Basic Patent
Records Containing Equivalent Chemical Indexing
in CA/Caplus

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN customer
agreement. This agreement limits use to scientific research. Use
for software development or design, implementation of commercial
gateways, or use of CAS and STN data in the building of commercial
products is prohibited and may result in loss of user privileges
and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 13:04:09 ON 11 JAN 2010

=> file reg		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.22	0.22

FILE 'REGISTRY' ENTERED AT 13:04:30 ON 11 JAN 2010
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2010 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 10 JAN 2010 HIGHEST RN 1201787-64-5
DICTIONARY FILE UPDATES: 10 JAN 2010 HIGHEST RN 1201787-64-5

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2009.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\STNEXP\Queries\10-516,777-1a.str



chain nodes :

9 10 21

ring nodes :

1 2 3 4 5 6 7 8 11 12 13 14 15 16 17 18 19

chain bonds :

9-10 9-11 9-21

ring bonds :

1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 7-8 11-12 11-15 12-13 13-14 13-16
14-15 14-19 16-17 17-18 18-19

exact/norm bonds :

1-2 1-6 1-8 2-3 3-4 4-5 4-7 5-6 7-8 9-10 9-11 9-21 11-12 11-15 12-13
14-15
normalized bonds :
13-14 13-16 14-19 16-17 17-18 18-19

G1:O,S

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:CLASS 10:CLASS
11:Atom 12:Atom 13:Atom 14:Atom 15:Atom 16:Atom 17:Atom 18:Atom 19:Atom
21:CLASS 22:Atom

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

*** STRUCTURE DIAGRAM IS NOT AVAILABLE ***

Structure attributes must be viewed using STN Express query preparation.

=> s l1 sss sam

SAMPLE SEARCH INITIATED 13:04:55 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 118 TO ITERATE

100.0% PROCESSED 118 ITERATIONS

29 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**

PROJECTED ITERATIONS: 1709 TO 3011

PROJECTED ANSWERS: 257 TO 903

L2 29 SEA SSS SAM L1

=> s l1 sss full

FULL SEARCH INITIATED 13:05:04 FILE 'REGISTRY'

FULL SCREEN SEARCH COMPLETED - 2162 TO ITERATE

100.0% PROCESSED 2162 ITERATIONS

676 ANSWERS

SEARCH TIME: 00.00.01

L3 676 SEA SSS FUL L1

=> file caplus

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

191.54

191.76

FILE 'CAPLUS' ENTERED AT 13:05:17 ON 11 JAN 2010

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2010 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 11 Jan 2010 VOL 152 ISS 3
FILE LAST UPDATED: 10 Jan 2010 (20100110/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2009
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2009

CAPLUS now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2009.

CAS Information Use Policies apply and are available at:

<http://www.cas.org/legal/infopolicy.html>

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s l3

L4 22 L3

=> d ibib abs hitstr 1-

YOU HAVE REQUESTED DATA FROM 22 ANSWERS - CONTINUE? Y/(N):y

L4 ANSWER 1 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1500693 CAPLUS

DOCUMENT NUMBER: 152:1877

TITLE: Methods using compounds having nicotinic acetylcholine receptor activity for treating disease-induced ataxia and non-ataxic imbalance

INVENTOR(S): Zesiewicz, Theresa A.; Sullivan, Kelly L.

PATENT ASSIGNEE(S): University of South Florida, USA

SOURCE: PCT Int. Appl., 63pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009146031	A1	20091203	WO 2009-US38948	20090331
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRIORITY APPLN. INFO.:			US 2008-41069P	P 20080331
			US 2008-41408P	P 20080401
			US 2008-43522P	P 20080409

US 2008-56173P P 20080527

US 2008-76343P P 20080627

AB Methods for treatment of disease-induced ataxia and non-ataxic imbalance are disclosed. The methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity.


IT 639494-67-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(TC 5619; nicotinic acetylcholine receptor compds. for treatment of disease-induced ataxia and non-ataxic imbalance)

RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1468018 CAPLUS

DOCUMENT NUMBER: 152:1868

TITLE: Method of treating peripheral nerve sensory loss using compounds having nicotinic acetylcholine receptor activity

INVENTOR(S): Zesiewicz, Theresa A.; Sullivan, Kelly L.; Ramsey, John Edward

PATENT ASSIGNEE(S): University of South Florida, USA

SOURCE: PCT Int. Appl., 54pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009143019	A2	20091126	WO 2009-US44155	20090515
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			

PRIORITY APPLN. INFO.: US 2008-55692P P 20080523

AB Methods for treatment of peripheral nerve sensory loss are disclosed. The

methods involve treating a patient with a compound having nicotinic acetylcholine receptor activity. Two patients with atypical Friedreich ataxia experienced modest proprioceptive improvements in their extremities within a month of taking varenicline, a drug approved for smoking cessation.

IT 639494-67-0, TC 5619
 RL: BSU (Biological study, unclassified); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (as compound having nicotinic acetylcholine receptor activity; peripheral nerve sensory loss treatment using compds. having nicotinic acetylcholine receptor activity)
 RN 639494-67-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



L4 ANSWER 3 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:1168740 CAPLUS
 DOCUMENT NUMBER: 151:373961
 TITLE: Method and compositions using $\alpha 7$ nicotinic acetylcholine receptor modulators for treatment of inflammatory disorders, including cerebral malaria
 INVENTOR(S): Bencherif, Merouane
 PATENT ASSIGNEE(S): USA
 SOURCE: U.S. Pat. Appl. Publ., 11pp.
 CODEN: USXXCO
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090239901	A1	20090924	US 2009-407010	20090319
PRIORITY APPLN. INFO.:			US 2008-37860P	P 20080319


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The invention discloses a method for treating inflammatory disorders, including cerebral malaria, by administration of modulators of $\alpha 7$ nicotinic acetylcholine receptor.

IT 639489-84-2
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 ($\alpha 7$ nicotinic acetylcholine receptor modulators for treatment of inflammatory disorders, including cerebral malaria)

RN 639489-84-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 4 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1072275 CAPLUS

DOCUMENT NUMBER: 151:280270

TITLE: Compositions for treatment of cognitive disorders

INVENTOR(S): Rueter, Lynne E.; Fox, Gerald B.; Browman, Kaitlin E.; Sullivan, James P.; Brioni, Jorge D.; Cowart, Marlon D.; Faghih, Ramin; Gfesser, Gregory A.; Mortell, Kathleen H.; Gopalakrishnan, Murali

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: U.S. Pat. Appl. Publ., 33pp.; Chemical Indexing Equivalent to 151:116642 (WO)
CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 4

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20090221648	A1	20090903	US 2008-338865	20081218
WO 2009082698	A1	20090702	WO 2008-US87729	20081219
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				


PRIORITY APPLN. INFO.:
 US 2007-15996P P 20071221
 US 2007-17388P P 20071228
 US 2008-338849 A 20081218
 US 2008-338865 A 20081218

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention relates to compns. for treatment of cognitive deficits. Such compns. can have a nicotinic acetylcholine receptor ligand, of either $\alpha 4\beta 2$ subtype or $\alpha 7$ nicotinic acetylcholine subtype, and a histamine-3 receptor ligand, a method of using the same, and a related article of manufacture Combinations of such active agents with psychostimulants or monoamine reuptake inhibitors also is contemplated.

IT 639494-67-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pharmaceutical compns. for combination therapy of cognitive diseases)
 RN 639494-67-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



L4 ANSWER 5 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:1017144 CAPLUS
 DOCUMENT NUMBER: 151:272947
 TITLE: Combination of α 7-nicotinic agonists and
 antipsychotics for treatment of psychiatric disorders
 INVENTOR(S): Bencherif, Merouane; Gatto, Gregory J.; Hauser, Terry;
 Jordan, Kristen G.; Letchworth, Sharon R.
 PATENT ASSIGNEE(S): Targacept, Inc., USA
 SOURCE: PCT Int. Appl., 94pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009102962	A2	20090820	WO 2009-US34062	20090213
WO 2009102962	A3	20091008		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				

PRIORITY APPLN. INFO.: US 2008-28282P P 20080213

OTHER SOURCE(S): MARPAT 151:272947

AB The present invention relates to a synergistic combination of an α 7-nicotinic agonist and an antipsychotic agent, to pharmaceutical compns. and kits comprising such a combination and to methods for treatment or prevention of psychiatric disorders, particularly psychotic disorders, by administering said combination. Thus, a pharmaceutical composition was prepared by combining an α 7-nicotinic agonist (2S,3R)-N-[2-[(3-pyridinyl)methyl]-1-azabicyclo[2.2.2]oct-3-yl]benzofuran-2-carboxamide (Compound A) with an atypical antipsychotic drug clozapine in a pharmaceutically-acceptable carrier in amts. that deliver a

therapeutically-effective amount of each drug. Clozapine (3.0 mg/kg) and Compound A (0.1 mg/kg), when given individually to transgenic th(tk)/th(tk) mice, a model of human schizophrenia, had little effect on prepulse inhibition (PPI) or startle. In contrast, there was a significant main effect of clozapine plus Compound A. No synergistic effects were observed in control mice.

IT 639489-84-2 639494-67-0 1111941-88-8
 1111941-89-9 1111941-90-2 1111942-11-0
 1181294-21-2 1181294-24-5 1181294-25-6
 1181294-26-7 1181294-27-8 1181294-28-9
 1181294-29-0 1181294-30-3 1181294-31-4
 1181294-33-6


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(comps. comprising α 7-nicotinic agonists and antipsychotics for treatment or prevention of psychiatric disorders)

RN 639489-84-2 CAPLUS


CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



RN 1111941-88-8 CAPLUS


CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 7664-38-2

CMF H3 O4 P



RN 1111941-89-9 CAPLUS


CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2

Absolute stereochemistry.




CM 2

CRN 110-16-7


CMF C4 H4 O4

Double bond geometry as shown.



RN 1111941-90-2 CAPLUS
CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 1111942-11-0 CAPLUS
CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2
CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2


CRN 104-15-4

CMF C7 H8 O3 S




RN 1181294-21-2 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-24-5 CAPLUS

CN 2-Benzofurancarboxamide, 3-methyl-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-25-6 CAPLUS

CN 2-Benzofurancarboxamide, 5-nitro-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-26-7 CAPLUS

CN 2-Benzofurancarboxamide, 5-methoxy-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-27-8 CAPLUS

CN 2-Benzofurancarboxamide, 7-methoxy-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-28-9 CAPLUS

CN 2-Benzofurancarboxamide, 7-ethoxy-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-29-0 CAPLUS

CN 2-Benzofurancarboxamide, 5-chloro-3-methyl-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-30-3 CAPLUS

CN 2-Benzofurancarboxamide, 6-bromo-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




RN 1181294-31-4 CAPLUS

CN 2-Benzofurancarboxamide, 4-acetyl-7-methoxy-N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



RN 1181294-33-6 CAPLUS

CN Naphtho[2,1-b]furan-2-carboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



L4 ANSWER 6 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:1005288 CAPLUS

DOCUMENT NUMBER: 151:440493

TITLE: TC-5619: An $\alpha 7$ neuronal nicotinic receptor-selective agonist that demonstrates efficacy in animal models of the positive and negative symptoms and cognitive dysfunction of schizophrenia

AUTHOR(S): Hauser, T. A.; Kucinski, A.; Jordan, K. G.; Gatto, G. J.; Wersinger, S. R.; Hesse, R. A.; Stachowiak, E. K.; Stachowiak, M. K.; Papke, R. L.; Lippiello, P. M.; Bencherif, M.

CORPORATE SOURCE: Preclinical Research, Targacept, Inc., Winston-Salem, NC, 27101, USA

SOURCE: Biochemical Pharmacology (2009), 78(7), 803-812
CODEN: BCPA6; ISSN: 0006-2952

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB A growing body of evidence suggests that the $\alpha 7$ neuronal nicotinic receptor (NNR) subtype is an important target for the development of novel therapies to treat schizophrenia, offering the possibility to address not only the pos. but also the cognitive and neg. symptoms associated with the disease. In order to probe the relationship of $\alpha 7$ function to relevant behavioral correlates we employed TC-5619, a novel selective agonist for the $\alpha 7$ NNR subtype. TC-5619 binds with very high affinity to the $\alpha 7$ subtype and is a potent full agonist. TC-5619 has little or no activity at other nicotinic receptors, including the $\alpha 4\beta 2$, ganglionic ($\alpha 3\beta 4$) and muscle subtypes. The transgenic th(tk-)/th(tk-) mouse model that reflects many of the developmental, anatomical, and multi-transmitter biochem. aspects of schizophrenia was used to assess the antipsychotic effects of TC-5619. In these mice TC-5619 acted both alone and synergistically with the antipsychotic clozapine to correct impaired pre-pulse inhibition (PPI) and social behavior which model pos. and neg. symptoms, resp. Antipsychotic and cognitive effects of TC-5619 were also assessed in rats. Similar to the results in the transgenic mice, TC-5619 significantly reversed apomorphine-induced PPI deficits. In a novel object recognition paradigm in rats TC-5619 demonstrated long-lasting enhancement of memory over a wide dose range. These results suggest that $\alpha 7$ -selective agonists such as TC-5619, either alone or in combination with antipsychotics, could offer a new approach to treating the constellation of symptoms associated with schizophrenia, including cognitive dysfunction.

IT 639494-67-0, TC 5619


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)

(TC 5619; effect of $\alpha 7$ neuronal nicotinic receptor-selective agonist TC-5619 in animal model of pos. and neg. symptoms and cognitive dysfunction of schizophrenia)

RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 61 THERE ARE 61 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 7 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2009:827050 CAPLUS

DOCUMENT NUMBER: 151:132241

TITLE: Transdermal therapeutic system having a content of a
modulator for nicotinic acetylcholine receptors
(nAChR)

INVENTOR(S): Meyer, Elisabeth; Tisa-Bostedt, Katalin; Beckert,
Thomas

PATENT ASSIGNEE(S): Acino A.-G., Germany

SOURCE: Ger. Offen., 12pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 102007058504	A1	20090709	DE 2007-102007058504	20071205
WO 2009071326	A2	20090611	WO 2008-EP10380	20081205
WO 2009071326	A3	20091001		

W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ,
CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES,
FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE,
KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH,
PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA

PRIORITY APPLN. INFO.: DE 2007-102007058504A 20071205

AB The invention relates to a transdermal therapeutic system (TTS) having a
content of at least one modulator for nicotinic acetylcholine receptors
(nAChR modulator). Thus a matrix was prepared by dissolving 5-15 weight%
epibatidine in ethylmethylketone (1: 4.2); 0.1-20 weight% Aloe vera extract was
added as penetration enhancer along with Durotak DT-6173. The homogenized
mixture was applied onto a polyester foil, dried and covered with a
siliconized foil.


IT 634904-39-5

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
(Biological study); USES (Uses)


(ABBF; transdermal therapeutic system having a content of a modulator

for nicotinic acetylcholine receptors (nAChR))
 RN 634904-39-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 639494-67-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (transdermal therapeutic system having a content of a modulator for nicotinic acetylcholine receptors (nAChR))
 RN 639494-67-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)




REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 8 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:796430 CAPLUS
 DOCUMENT NUMBER: 151:116642
 TITLE: Compositions containing a nicotinic $\alpha 7$ subunit or a nicotinic $\alpha 4\beta 2$ receptor ligand and a histamine-3 receptor ligand for treatment of cognitive disorders
 INVENTOR(S): Rueter, Lynne E.; Fox, Gerard B.; Browman, Kaitlin E.; Sullivan, James P.; Brioni, Jorge D.; Cowart, Marlon D.; Faghieh, Ramin; Gfesser, Gregory A.; Mortell, Kathleen H.; Gopalakrishnan, Murali
 PATENT ASSIGNEE(S): Abbott Laboratories, USA
 SOURCE: PCT Int. Appl., 96pp.; Chemical Indexing Equivalent to 151:280270 (US)
 CODEN: PIXXD2

DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 4
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009082698	A1	20090702	WO 2008-US87729	20081219
W:	AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
US 20090163470	A1	20090625	US 2008-338849	20081218
US 20090221648	A1	20090903	US 2008-338865	20081218
PRIORITY APPLN. INFO.:			US 2007-15996P	P 20071221
			US 2007-17388P	P 20071228
			US 2008-338849	A 20081218
			US 2008-338865	A 20081218
OTHER SOURCE(S):	MARPAT 151:116642			
GI				



AB The invention is related to compns. containing a nicotinic $\alpha 7$ subunit of formula I [R1 = H, Me, Ph, pyrazolyl, OH; R2 = OH, :CH2, :CHRC, (un)substituted alk(en)yl; Rc = alkyl, halo; R3 = (un)substituted (hetero)aryl, G1-L-G2; G1 = (hetero)arylene; L = a bond, O, alkylene, alkoxylen; G2 = (hetero)aryl, cycloalkyl, heterocyclyl; R4 = (un)substituted cyclo/alkyl, heteroaryl, heterocyclyl, NH2 and derivs. with provisos] or a nicotinic $\alpha 4\beta 2$ receptor ligand and a histamine-3 receptor ligand for treatment of cognitive deficits. The invention is also related to combinations of such active agents with psychostimulants or monoamine reuptake inhibitors. The $\alpha 7$ ligand 2-methyl-5-(6-phenylpyridazin-3-yl)octahydropyrrolo[3,4-c]pyrrole induced a significant, dose dependent effect, with the dose of 1 μ mol/kg increasing transfer latency, while the reuptake inhibitor atomoxetine did not alter the transfer latency, demonstrating that adding treatment with an $\alpha 7$ receptor ligand to treatment wit reuptake inhibitors will result in greater clin. efficacy than that seen with reuptake inhibitors alone.

IT 639494-67-0

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (pharmaceutical comps. for combination therapy of cognitive diseases)
 RN 639494-67-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS
 RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 9 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:708100 CAPLUS
 DOCUMENT NUMBER: 151:42043
 TITLE: Transdermal therapeutic system having a content of a
 modulator for nicotinic acetylcholine receptors
 (nAChR)
 INVENTOR(S): Meyer, Elisabeth; Tisa-Bostedt, Katalin; Beckert,
 Thomas
 PATENT ASSIGNEE(S): Acino A.-G., Germany
 SOURCE: PCT Int. Appl., 30 pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009071326	A2	20090611	WO 2008-EP10380	20081205
WO 2009071326	A3	20091001		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
DE 102007058504	A1	20090709	DE 2007-102007058504	20071205

PRIORITY APPLN. INFO.: DE 2007-102007058504A 20071205


AB The invention relates to a transdermal therapeutic system (TTS) having a
 content of at least one modulator for nicotinic acetylcholine receptors
 (nAChR modulator). Thus a matrix was prepared by dissolving 5-15 weight%
 epibatidine in ethylmethylketone (1: 4.2); 0.1-20 weight% Aloe vera extract was
 added as penetration enhancer along with Durotak DT-6173. The homogenized
 mixture was applied onto a polyester foil, dried and covered with a

siliconized foil.
 IT 634904-39-5
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (ABBF; transdermal therapeutic system having a content of a modulator
 for nicotinic acetylcholine receptors (nAChR))
 RN 634904-39-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-
 methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 639494-67-0
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL
 (Biological study); USES (Uses)
 (transdermal therapeutic system having a content of a modulator for
 nicotinic acetylcholine receptors (nAChR))
 RN 639494-67-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-
 yl]- (CA INDEX NAME)



L4 ANSWER 10 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:143404 CAPLUS
 DOCUMENT NUMBER: 150:206370
 TITLE: Treatment with $\alpha 7$ nAChR-selective ligands
 INVENTOR(S): Bencherif, Merouane; Marrero, Mario B.
 PATENT ASSIGNEE(S): Targacept, Inc., USA; Medical College of Georgia
 SOURCE: PCT Int. Appl., 103pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009018511	A2	20090205	WO 2008-US71893	20080801
WO 2009018511	A3	20090423		
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW				
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA				
US 20090048290	A1	20090219	US 2008-184312	20080801
PRIORITY APPLN. INFO.:			US 2007-953610P	P 20070802
			US 2007-953613P	P 20070802
			US 2007-953614P	P 20070802
			US 2007-971654P	P 20070912

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB The present invention includes methods, uses, and selective $\alpha 7$ nAChR agonist compds. for treating or preventing metabolic disorders.


IT 639489-84-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(treatment with $\alpha 7$ nAChR-selective agonists)

RN 639489-84-2 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 1111941-90-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(treatment with $\alpha 7$ nAChR-selective agonists)

RN 1111941-90-2 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.




● HCl

IT 1111942-11-0P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (treatment with $\alpha 7$ nAChR-selective agonists)
 RN 1111942-11-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-
 azabicyclo[2.2.2]oct-3-yl]-, 4-methylbenzenesulfonate (1:1) (CA INDEX
 NAME)
 CM 1
 CRN 639489-84-2
 CMF C22 H23 N3 O2

Absolute stereochemistry.




CM 2
 CRN 104-15-4
 CMF C7 H8 O3 S



IT 639489-82-0P
 RL: SPN (Synthetic preparation); PREP (Preparation)
 (treatment with $\alpha 7$ nAChR-selective agonists)
 RN 639489-82-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



L4 ANSWER 11 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN
 ACCESSION NUMBER: 2009:138975 CAPLUS
 DOCUMENT NUMBER: 150:214178
 TITLE: Preparation of
 (2S,3R)-N-[2-(3-pyridylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzofuran-2-carboxamide and salts as neuronal
 nicotinic receptor $\alpha 7$ ligands.
 INVENTOR(S): Bencherif, Merouane; Benson, Lisa; Dull, Gary Maurice;
 Fedorov, Nikolai; Gatto, Gregory J.; Genus, John;
 Jordan, Kristen G.; Mathew, Jacob; Mazurov, Anatoly
 A.; Miao, Lan; Munoz, Julio A.; Pfeiffer, Inigo;
 Pfeiffer, Sondra; Phillips, Teresa Y.
 PATENT ASSIGNEE(S): Targacept, Inc., USA
 SOURCE: PCT Int. Appl., 81pp.
 CODEN: PIXXD2
 DOCUMENT TYPE: Patent
 LANGUAGE: English
 FAMILY ACC. NUM. COUNT: 2
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2009018505	A1	20090205	WO 2008-US71872	20080801
W: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ,				

TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU,
 IE, IS, IT, LT, LU, LV, MC, MT, NL, NO, PL, PT, RO, SE, SI, SK,
 TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
 TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW,
 AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

US 20090048290 A1 20090219 US 2008-184312 20080801
 PRIORITY APPLN. INFO.: US 2007-953610P P 20070802
 US 2007-953613P P 20070802
 US 2007-953614P P 20070802
 US 2007-971654P P 20070912


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

AB (2S,3R)-N-[2-(3-pyridylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]benzofuran-2-
 carboxamide (I) and salts were prepared Thus,
 (2S,3R)-3-amino-2-(3-pyridylmethyl)-1-azabicyclo[2.2.2]octane (preparation
 given), benzofuran-2-carboxylic acid, Et3N, and HBTU were stirred 4 h in
 CH2Cl2 to give 77% I. I competitively inhibits binding of radiolabeled
 MMA to rat brain hippocampus $\alpha 7$ NNRs with $K_i = 1$ nM.
 IT 1111942-11-0P
 RL: PAC (Pharmacological activity); PRP (Properties); RCT (Reactant); SPN
 (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study);
 PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide
 and salts as neuronal nicotinic receptor $\alpha 7$ ligands)
 RN 1111942-11-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-
 azabicyclo[2.2.2]oct-3-yl]-, 4-methylbenzenesulfonate (1:1) (CA INDEX
 NAME)

CM 1


CRN 639489-84-2
 CMF C22 H23 N3 O2

Absolute stereochemistry.




CM 2

CRN 104-15-4
 CMF C7 H8 O3 S



IT 1111941-90-2P
 RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide and salts as neuronal nicotinic receptor $\alpha 7$ ligands)
 RN 1111941-90-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 639489-84-2P
 RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide and salts as neuronal nicotinic receptor $\alpha 7$ ligands)
 RN 639489-84-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 1111941-88-8P 1111941-89-9P 1111941-91-3P
 1111941-93-5P 1111941-94-6P 1111941-95-7P
 1111941-96-8P 1111941-97-9P 1111941-98-0P
 1111941-99-1P 1111942-00-7P 1111942-01-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
 (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
 (Uses)

(preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide
 and salts as neuronal nicotinic receptor $\alpha 7$ ligands)

RN 1111941-88-8 CAPLUS


CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-
 azabicyclo[2.2.2]oct-3-yl]-, phosphate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2


CRN 7664-38-2

CMF H3 O4 P




RN 1111941-89-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, (2Z)-2-butenedioate (1:1) (CA INDEX NAME)
 CM 1
 CRN 639489-84-2
 CMF C22 H23 N3 O2

Absolute stereochemistry.




CM 2
 CRN 110-16-7
 CMF C4 H4 O4

Double bond geometry as shown.



RN 1111941-91-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 1111941-93-5 CAPLUS
 CN Galactaric acid, compd. with N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-2-benzofurancarboxamide (1:2) (CA INDEX NAME)

CM 1

CRN 639489-84-2
 CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 526-99-8
 CMF C6 H10 O8

Relative stereochemistry.




RN 1111941-94-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, (2S,3S)-2,3-dihydroxybutanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2
 CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 147-71-7
 CMF C4 H6 O6

Absolute stereochemistry.




RN 1111941-95-7 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, methanesulfonate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2
 CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 1111941-96-8 CAPLUS


CN Benzeneacetic acid, α -hydroxy-, (α R)-, compd. with
N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-2-
benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2

Absolute stereochemistry.




CM 2

CRN 611-71-2

CMF C8 H8 O3

Absolute stereochemistry. Rotation (-).




RN 1111941-97-9 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,
(1R,4S)-, compd. with N-[(2S,3R)-2-(3-pyridinylmethyl)-1-
azabicyclo[2.2.2]oct-3-yl]-2-benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2
CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 35963-20-3
CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (-).




RN 1111941-98-0 CAPLUS
CN Bicyclo[2.2.1]heptane-1-methanesulfonic acid, 7,7-dimethyl-2-oxo-,
(1S,4R)-, compd. with N-[(2S,3R)-2-(3-pyridinylmethyl)-1-
azabicyclo[2.2.2]oct-3-yl]-2-benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2

Absolute stereochemistry.




CM 2

CRN 3144-16-9

CMF C10 H16 O4 S

Absolute stereochemistry. Rotation (+).



RN 1111941-99-1 CAPLUS


CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, sulfate (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 1111942-00-7 CAPLUS


CN Pentanedioic acid, 2-oxo-, compd. with
N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-2-
benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 328-50-7

CMF C5 H6 O5



RN 1111942-01-8 CAPLUS


CN Glycine, N-benzoyl-, compd. with N-[(2S,3R)-2-(3-pyridinylmethyl)-1-
azabicyclo[2.2.2]oct-3-yl]-2-benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-84-2

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 495-69-2

CMF C9 H9 N O3



IT 1111942-04-1P

RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide
and salts as neuronal nicotinic receptor $\alpha 7$ ligands)

RN 1111942-04-1 CAPLUS


CN Benzoic acid, 4-chloro-, compd. with
N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-2-
benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-80-8

CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2


CRN 74-11-3

CMF C7 H5 Cl O2




IT 639489-80-8P 639489-86-4P 1111942-02-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)
(preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide
and salts as neuronal nicotinic receptor $\alpha 7$ ligands)
RN 639489-80-8 CAPLUS
CN 2-Benzofurancarboxamide, N-[(2R,3R)-2-(3-pyridinylmethyl)-1-
azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 639489-86-4 CAPLUS
CN 2-Benzofurancarboxamide, N-[(2S,3S)-2-(3-pyridinylmethyl)-1-
azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1111942-02-9 CAPLUS
CN Galactaric acid, compd. with N-[(2R,3R)-2-(3-pyridinylmethyl)-1-
azabicyclo[2.2.2]oct-3-yl]-2-benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-80-8

CMF C22 H23 N3 O2

Absolute stereochemistry.




CM 2

CRN 526-99-8

CMF C6 H10 O8

Relative stereochemistry.



IT 639489-82-0P 1111942-03-0P


RL: SPN (Synthetic preparation); PREP (Preparation)

(preparation of chiral pyridylmethylazabicyclooctyl benzofurancarboxamide and salts as neuronal nicotinic receptor $\alpha 7$ ligands)

RN 639489-82-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 1111942-03-0 CAPLUS
 CN Galactaric acid, compd. with N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-2-benzofurancarboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 639489-86-4
 CMF C22 H23 N3 O2


Absolute stereochemistry.



CM 2

CRN 526-99-8
 CMF C6 H10 O8

Relative stereochemistry.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
 REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 12 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2007:513292 CAPLUS

DOCUMENT NUMBER: 147:109919

TITLE: The novel $\alpha 7$ nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents

AUTHOR(S): Boess, Frank G.; De Vry, Jean; Erb, Christina; Flessner, Timo; Hendrix, Martin; Luithle, Joachim; Methfessel, Christoph; Riedl, Bernd; Schnizler, Katrin; van der Staay, Franz-Josef; van Kampen, Marja; Wiese, Welf Burkhard; Koenig, Gerhard

CORPORATE SOURCE: Pharma Research CNS, Bayer HealthCare AG, Wuppertal, Germany

SOURCE: Journal of Pharmacology and Experimental Therapeutics (2007), 321(2), 716-725

CODEN: JPETAB; ISSN: 0022-3565

PUBLISHER: American Society for Pharmacology and Experimental Therapeutics

DOCUMENT TYPE: Journal

LANGUAGE: English

AB The relative contribution of $\alpha 4\beta 2$, $\alpha 7$ and other nicotinic acetylcholine receptor (nAChR) subtypes to the memory enhancing vs. the addictive effects of nicotine is the subject of ongoing debate. In the present study, we characterized the pharmacol. and behavioral properties of the $\alpha 7$ nAChR agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide (ABBF). ABBF bound to $\alpha 7$ nAChR in rat brain membranes ($K_i = 62$ nM) and to recombinant human 5-hydroxytryptamine (5-HT)₃ receptors ($K_i = 60$ nM). ABBF was a potent agonist at the recombinant rat and human $\alpha 7$ nAChR expressed in *Xenopus* oocytes, but it did not show agonist activity at other nAChR subtypes. ABBF acted as an antagonist of the 5-HT₃ receptor and $\alpha 3\beta 4$, $\alpha 4\beta 2$, and muscle nAChRs (at higher concns.). ABBF improved social recognition memory in rats (0.3-1 mg/kg p.o.). This improvement was blocked by intracerebroventricular administration of the $\alpha 7$ nAChR antagonist methyllycaconitine at 10 μ g, indicating that it is mediated by $\alpha 7$ nAChR agonism. In addition, ABBF improved working memory of aged rats in a water maze repeated acquisition paradigm (1 mg/kg p.o.) and object recognition memory in mice (0.3-1 mg/kg p.o.). Rats trained to discriminate nicotine (0.4 mg/kg s.c.) from vehicle did not generalize to ABBF (0.3-30 mg/kg p.o.), suggesting that the nicotine cue is not mediated by the $\alpha 7$ nAChR and that selective $\alpha 7$ nAChR agonists may not share the abuse liability of nicotine. Our results support the hypothesis that $\alpha 7$ nAChR agonists may provide a novel therapeutic strategy for the treatment of cognitive deficits with low abuse potential.

IT 634904-11-3


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

($\alpha 7$ nicotinic acetylcholine receptor agonist
[azabicyclooctyl][(methoxy)phenyl]benzofurancarboxamide improves memory with low abuse potential in rodents)

RN 634904-11-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

OS.CITING REF COUNT: 35 THERE ARE 35 CAPLUS RECORDS THAT CITE THIS
RECORD (35 CITINGS)
REFERENCE COUNT: 42 THERE ARE 42 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 13 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2007:228801 CAPLUS
DOCUMENT NUMBER: 146:462113
TITLE: Novel 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivatives as selective α_2C -adrenergic receptor antagonists
AUTHOR(S): Hagiwara, Koji; Kashima, Hajime; Iida, Kyoichiro; Enokizono, Junichi; Uchida, Shin-ichi; Nonaka, Hiromi; Kurokawa, Masako; Shimada, Junichi
CORPORATE SOURCE: Pharmaceutical Research Center, Kyowa Hakko Kogyo Co., Ltd, 1188 Shimotogari, Nagaizumi-cho, Sunto-gun, Shizuoka, 411-8731, Japan
SOURCE: Bioorganic & Medicinal Chemistry Letters (2007), 17(6), 1616-1621
CODEN: BMCLE8; ISSN: 0960-894X
PUBLISHER: Elsevier Ltd.
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 146:462113
GI



AB The synthesis of a series of 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methyl-2-arylbenzofuran and 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran-2-carboxamide derivs. as novel α_2 C-adrenergic receptor antagonists are described. Their affinity at three different human α_2 -adrenergic receptors is reported, and some of these compds. exhibited high affinity for the α_2 C-adrenergic receptor with high subtype selectivity. Among them, the monofumarate of compound I has been found to show the anti-L-dopa-induced dyskinetic activity in marmosets. The structure-activity relationship of these compds. is also discussed.

IT 934969-56-9P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of 4-(6,7-dimethoxy-1,2,3,4-tetrahydroisoquinolin-2-yl)methylbenzofuran derivs. as selective α_2 C-adrenergic receptor antagonists)

RN 934969-56-9 CAPLUS


CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-[(3,4-dihydro-6,7-dimethoxy-2(1H)-isoquinolinyl)methyl]-7-methoxy-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 934969-55-8

CMF C29 H35 N3 O5

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 14 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:1313798 CAPLUS

DOCUMENT NUMBER: 146:454924

TITLE: Therapeutic potential of novel selective drugs in targeting nicotinic acetylcholine receptors

AUTHOR(S): Bencherif, Merouane; Hauser, Terry A.; Jordan, Kristen G.; Gatto, Gregory J.

CORPORATE SOURCE: Preclinical Research, Targacept, Inc., Winston-Salem, NC, 27101, USA

SOURCE: Journal of Molecular Neuroscience (2006), 30(1-2), 17-18

CODEN: JMNEES; ISSN: 0895-8696

PUBLISHER: Humana Press Inc.

DOCUMENT TYPE: Journal

LANGUAGE: English

AB Investigation of $\alpha 7$ functional activity showed a full range of activities from antagonists to full agonists without any significant activity at the human 5-HT3 receptor, P 450 isoenzymes, hERG channels, or in the AMES test. Results demonstrate that potent and highly selective nAChR ligands can be designed. It is now clear that various combinations of nAChR pharmacologies can be recruited within a single mol. to optimize efficacy by targeting relevant symptomatology and minimize undesired interactions.


IT 639494-67-0, TC 5619

RL: DMA (Drug mechanism of action); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(therapeutic potential of novel selective drugs in targeting nicotinic receptors)

RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS

RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 15 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2006:980050 CAPLUS

DOCUMENT NUMBER: 145:328406

TITLE: Neuronal $\alpha 7$ nicotinic receptor ligand and antipsychotic compositions for treatment of schizophrenia

INVENTOR(S): Kohlhaas, Kathy L.; Rueter, Lynne E.; Bitner, R. Scott

PATENT ASSIGNEE(S): Abbott Laboratories, USA

SOURCE: U.S. Pat. Appl. Publ., 37pp.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060211686	A1	20060921	US 2006-370419	20060308
CA 2601509	A1	20060928	CA 2006-2601509	20060308
WO 2006101745	A2	20060928	WO 2006-US8289	20060308
WO 2006101745	A3	20070125		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
EP 1863485	A2	20071212	EP 2006-737458	20060308
R:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL, BA, HR, MK, YU			
JP 2008533142	T	20080821	JP 2008-501915	20060308
MX 2007011436	A	20071012	MX 2007-11436	20070917
PRIORITY APPLN. INFO.:			US 2005-663184P	P 20050318
			WO 2006-US8289	W 20060308


ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 145:328406

AB The present invention relates to a composition comprising an antipsychotic agent and a neuronal $\alpha 7$ nicotinic acetylcholine receptor ligand, a method of using the same for treatment of psychotic conditions, such as schizophrenia, and a related article of manufacture. The neuronal $\alpha 7$ nicotinic receptor ligand, i.e., a nicotinic agonist, a nicotinic partial agonist, or a nicotinic allosteric modulator is selected from diazabicycloalkane derivs., spirocyclic quinuclidinic ether derivs., bicycloheterocycle-substituted quinuclidine derivs., 3-quinuclidinyl amino-substituted biaryl derivs., 3-quinuclidinyl heteroatom-bridged biaryl derivs., and amino-substituted tricyclic derivs. Thus, nicotinic $\alpha 7$ receptor agonist 5-(6-[(3R)-1-azabicyclo[2.2.2]oct-3-yloxy]pyridazin-3-yl)-1H-indole (Compound 1) potentiated antipsychotic effect of sub-efficacious dose of risperidone in mouse model of schizophrenia. Compound 1 alone at 0.04 mg/kg did not have an effect, but when combined with a sub-efficacious dose of risperidone (0.1 mg/kg), a maximally efficacious response was achieved. Such a response was similar to that achieved by a 10-fold higher dose of risperidone (1.0 mg/kg). The

results demonstrated that a dose that was normally weakly efficacious could be made to exhibit robust efficacy upon $\alpha 7$ receptor activation by an agonist. The plasma concentration of Compound 1 required to achieve this effect was less than 100 nM.

IT 639494-67-0, TC 5619
 RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
 (compsns. comprising antipsychotic and neuronal $\alpha 7$ nicotinic receptor ligand for treatment of schizophrenia and related disorders)
 RN 639494-67-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD (3 CITINGS)

L4 ANSWER 16 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:1024915 CAPLUS

DOCUMENT NUMBER: 143:452150

TITLE: High affinity ligands for the $\alpha 7$ nicotinic receptor that show no cross-reactivity with the 5-HT3 receptor

AUTHOR(S): Baker, S. Richard; Boot, John; Brunavs, Michael; Dobson, David; Green, Rachel; Hayhurst, Lorna; Keenan, Martine; Wallace, Louise

CORPORATE SOURCE: Lilly Research Centre, Eli Lilly and Company Ltd., Surrey, GU20 6PH, UK

SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(21), 4727-4730

CODEN: BMCLE8; ISSN: 0960-894X

PUBLISHER: Elsevier B.V.

DOCUMENT TYPE: Journal

LANGUAGE: English

OTHER SOURCE(S): CASREACT 143:452150


AB Potent and selective ligands of the $\alpha 7$ nicotinic acetylcholine receptor are required to understand the pharmacol. effect of $\alpha 7$ activation. A common cross-reactivity occurs with serotonergic 5-HT3 receptors with which $\alpha 7$ receptors have a high sequence homol. The authors demonstrate that certain quinuclidine 3-biaryl carboxamides are high affinity $\alpha 7$ ligands with an excellent binding selectivity over 5-HT3 receptors.

IT 550998-91-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(high affinity ligands for $\alpha 7$ nicotinic receptor showing no cross-reactivity with 5-HT3 receptor)

RN 550998-91-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)



OS.CITING REF COUNT: 3 THERE ARE 3 CAPLUS RECORDS THAT CITE THIS RECORD
(3 CITINGS)
REFERENCE COUNT: 25 THERE ARE 25 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 17 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:979654 CAPLUS

DOCUMENT NUMBER: 143:266925

TITLE: Preparation of imidazo[4,5-b]pyridine derivatives as
GPR4 receptor antagonists

INVENTOR(S): Iida, Kyoichiro; Otsubo, Nobumasa; Kuboyama, Takeshi;
Arai, Hitoshi; Watanabe, Akihiko; Saki, Mayumi; Hiura,
Naoko; Manabe, Haruhiko; Takada, Hidenori; Saito, Jun

PATENT ASSIGNEE(S): Kyowa Hakko Kogyo Co., Ltd., Japan

SOURCE: PCT Int. Appl., 215 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: Japanese

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005082905	A1	20050909	WO 2005-JP3687	20050225
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			

PRIORITY APPLN. INFO.: JP 2004-50933 A 20040226
JP 2004-307947 A 20041022

OTHER SOURCE(S): MARPAT 143:266925

GI



AB The title compds. I [wherein R1 = H, halo, NH2, etc.; R2-R4 = independently H, halo, CN, etc.; Y = N or (un)substituted CH; X = (un)substituted NH; Z1-Z4 = independently N or (un)substituted CH; W = NO2, CHO, (un)substituted alkyl, etc.] or pharmaceutically acceptable salts thereof are prepared as G protein-coupled receptor (GPR4) antagonists for the treatment of neutrophil inflammation. For example, the compound II was prepared in a multi-step synthesis. II inhibited 98% of human GPR4 at the concentration of 1 μ M.


IT 863876-47-5P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(drug candidate; preparation of imidazo[4,5-b]pyridine derivs. as GPR4 receptor antagonists)

RN 863876-47-5 CAPLUS

CN 2-Benzofurancarboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-5-[(2-ethyl-5,7-dimethyl-3H-imidazo[4,5-b]pyridin-3-yl)methyl]-7-methoxy- (CA INDEX NAME)



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)

REFERENCE COUNT: 6 THERE ARE 6 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 18 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2005:286359 CAPLUS

DOCUMENT NUMBER: 143:19236

TITLE: 2-(Arylmethyl)-3-substituted quinuclidines as selective α 7 nicotinic receptor ligands

AUTHOR(S): Mazurov, Anatoly; Klucik, Jozef; Miao, Lan; Phillips, Teresa Y.; Seamans, Angela; Schmitt, Jeffrey D.; Hauser, Terry A.; Johnson, Raymond T.; Miller, Craig

CORPORATE SOURCE: Medicinal Chemistry, Targacept, Inc., Winston-Salem, NC, 27101, USA
 SOURCE: Bioorganic & Medicinal Chemistry Letters (2005), 15(8), 2073-2077
 CODEN: BMCLE8; ISSN: 0960-894X
 PUBLISHER: Elsevier B.V.
 DOCUMENT TYPE: Journal
 LANGUAGE: English
 OTHER SOURCE(S): CASREACT 143:19236

AB A series of 2-(arylmethyl)-3-substituted quinuclidines was developed as $\alpha 7$ neuronal nicotinic acetylcholine receptor (nAChR) agonists based on a putative pharmacophore model. The series is highly selective for the $\alpha 7$ over other nAChRs (e.g., the $\alpha 4\beta 2$ of the CNS, and the muscle and ganglionic subtypes) and is functionally tunable at $\alpha 7$. One member of the series, (+)-N-(1-azabicyclo[2.2.2]oct-3-yl)benzo[b]furan-2-carboxamide, has potent agonistic activity for the $\alpha 7$ nAChR (EC50 = 33 nM, Imax = 1.0), at concns. below those that result in desensitization.

IT 852476-47-2P 852476-66-5P 852812-62-5P
 852812-63-6P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(arylmethyl-substituted quinuclidines as selective $\alpha 7$ nicotinic receptor ligands)

RN 852476-47-2 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 852476-66-5 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, rel- (CA INDEX NAME)


Relative stereochemistry.



RN 852812-62-5 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, rel-(+)- (CA INDEX NAME)


Rotation (+). Absolute stereochemistry unknown.



RN 852812-63-6 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]-, rel-(-)- (CA INDEX NAME)

Rotation (-). Absolute stereochemistry unknown.



OS.CITING REF COUNT: 10

THERE ARE 10 CAPLUS RECORDS THAT CITE THIS RECORD (10 CITINGS)

REFERENCE COUNT: 34

THERE ARE 34 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 19 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:117115 CAPLUS

DOCUMENT NUMBER: 140:181328

TITLE: Preparation of benzothiophenes, benzofuranes and indoles for improvement of cognition, attention achievement, learning achievement and/or memory achievement

INVENTOR(S): Flessner, Timo; Boess, Frank-Gerhard; Erb, Christina; Hafner, Frank-Thorsten; Schnizler, Katrin; Lang, Dieter; Luithle, Joachim; Van Kampen, Marja; Van der Staay, Franz-Josef

PATENT ASSIGNEE(S): Bayer AG, Germany

SOURCE: Ger. Offen., 35 pp.

CODEN: GWXXBX

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1


PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 10234424	A1	20040212	DE 2002-10234424	20020729
CA 2494352	A1	20040212	CA 2003-2494352	20030714
WO 2004013136	A1	20040212	WO 2003-EP7588	20030714
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
AU 2003254343	A1	20040223	AU 2003-254343	20030714
EP 1527073	A1	20050504	EP 2003-766162	20030714
EP 1527073	B1	20070822		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2005538111	T	20051215	JP 2004-525191	20030714
ES 2291694	T3	20080301	ES 2003-766162	20030714
US 20060106096	A1	20060518	US 2005-522611	20051215
PRIORITY APPLN. INFO.:			DE 2002-10234424	A 20020729
			WO 2003-EP7588	W 20030714

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:181328

GI



AB Title compds. [I; R1 = 1-azabicyclo[2.2.2]oct-3-yl; R2 = H, alkyl; R3 = H,

halo, amino, OH, C1-6 alkyl; R4 = H, (substituted) C1-6 alkyl; R5 = H, C1-6 alkyl; or R4R5 = (substituted) 5-6 membered heterocyclyl; R6 = H, alkyl, cycloalkyl, aryl, (substituted) 5-6 membered heterocyclyl, etc.; NR5R6 = (substituted) 3-8 membered heterocyclyl; A = O, N, S; X = O, S; B = (substituted) benzo or pyrido ring], were prepared Thus, 6-amino-N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-1-benzothiophene-2-carboxamide dihydrochloride (preparation given) in THF was reacted with Et3N and 2,6-difluorophenyl isocyanate for 18 h at room temperature to give 75.9% N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-[(2,6-difluorophenyl)aminocarbonylamino]-1-benzothiophene-2-carboxamide hydrochloride. The latter showed affinity to $\alpha 7$ -NACHR by inhibiting [3H]methyllycaconite binding in rat brain membranes with $K_i = 0.4$ nM.

IT 657401-24-6P 657401-25-7P 657401-26-8P
 657401-27-9P 657401-28-0P 657401-29-1P
 657401-30-4P 657401-31-5P 657401-32-6P
 657401-33-7P 657401-34-8P 657401-36-0P
 657401-37-1P 657401-38-2P 657401-39-3P
 657401-40-6P 657401-41-7P 657401-42-8P
 657401-43-9P 657401-44-0P 657401-45-1P
 657401-46-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of benzothiophenes, benzofuranes and indoles for improvement of cognition, attention achievement, learning achievement and/or memory achievement)

RN 657401-24-6 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[[(phenylamino)carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 657401-25-7 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[[[(4-chlorophenyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 657401-26-8 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[[[(2-methoxyphenyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 657401-27-9 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[[[(4-methoxyphenyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 657401-28-0 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-

[[[(2-phenylethyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 657401-29-1 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[[[(3-cyanophenyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 657401-30-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[[[(3-bromophenyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 657401-31-5 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
[[[(2-ethoxyphenyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX
NAME)


Absolute stereochemistry.



● HCl

RN 657401-32-6 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
[[[4-(dimethylamino)phenyl]amino]carbonyl]amino]-, hydrochloride (1:1)
(CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 657401-33-7 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
[[[(2-nitrophenyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX
NAME)


Absolute stereochemistry.



● HCl

RN 657401-34-8 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
 [[[2,6-difluorophenyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA
 INDEX NAME)


Absolute stereochemistry.



● HCl

RN 657401-36-0 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
 [[[2,4-dichlorophenyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA
 INDEX NAME)

Absolute stereochemistry.




● HCl

RN 657401-37-1 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-

[[[3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, hydrochloride (1:1)
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 657401-38-2 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[[[3,4,5-trimethoxyphenyl]amino]carbonyl]amino]-, hydrochloride (1:1)
(CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 657401-39-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[[[4-methoxy-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 657401-40-6 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[[[(3-methoxyphenyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 657401-41-7 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[[[3-(trifluoromethoxy)phenyl]amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 657401-42-8 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
[[[(1,1-dimethylethyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA
INDEX NAME)

Absolute stereochemistry.




● HCl

RN 657401-43-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
[[[(cyclohexylamino)carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 657401-44-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
[[[(1S)-1-phenylethyl]amino]carbonyl]amino]-, hydrochloride (1:1) (CA
INDEX NAME)


Absolute stereochemistry.



● HCl

RN 657401-45-1 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-
 [[(phenylamino)carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 657401-46-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[[[(4-methoxyphenyl)amino]carbonyl]amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl


IT 550998-69-1P 550998-99-7P 550999-21-8P
 550999-22-9P 550999-43-4P 550999-71-8P
 550999-80-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)

(preparation of benzothiophenes, benzofuranes and indoles for improvement of
 cognition, attention achievement, learning achievement and/or memory
 achievement)

RN 550998-69-1 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
 nitro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550998-99-7 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-21-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-nitro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-22-9 CAPLUS
 CN 2-Benzofurancarboxamide, 6-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-43-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-bromo-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-71-8 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, 7-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 550999-80-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, 6-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)

L4 ANSWER 20 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2004:3665 CAPLUS

DOCUMENT NUMBER: 140:77298

TITLE: Preparation of
3-substituted-2(arylalkyl)-1-azabicycloalkanes and
methods of treatment using these compounds

INVENTOR(S): Mazurov, Anatoly A.; Klucik, Jozef; Miao, Lan;
Seamans, Angela S.; Phillips, Teresa Youngpeter;
Schmitt, Jeffrey Daniel; Miller, Craig Harrison

PATENT ASSIGNEE(S): Targacept, Inc., USA

SOURCE: U.S. Pat. Appl. Publ., 38 pp., Cont.-in-part of U.S.
Ser. No. 162,129.

CODEN: USXXCO

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:


PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20040002513	A1	20040101	US 2003-372642	20030221
US 6953855	B2	20051011		
US 6432975	B1	20020813	US 1998-210113	19981211
US 20030045523	A1	20030306	US 2002-162129	20020604
AU 2004215386	A1	20040910	AU 2004-215386	20040220
AU 2004215386	B2	20090611		
CA 2514135	A1	20040910	CA 2004-2514135	20040220
WO 2004076449	A2	20040910	WO 2004-US5044	20040220
WO 2004076449	A3	20041216		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1594869	A2	20051116	EP 2004-713356	20040220
EP 1594869	B1	20071219		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2004007708	A	20060214	BR 2004-7708	20040220
CN 1751041	A	20060322	CN 2004-80004736	20040220
JP 2006518746	T	20060817	JP 2006-503737	20040220

PT 1594869	E	20080114	PT 2004-713356	20040220
AT 381563	T	20080115	AT 2004-713356	20040220
NZ 541794	A	20080328	NZ 2004-541794	20040220
ES 2300749	T3	20080616	ES 2004-713356	20040220
CN 101220026	A	20080716	CN 2007-10159889	20040220
NZ 565177	A	20080926	NZ 2004-565177	20040220
NZ 565178	A	20090531	NZ 2004-565178	20040220
US 20050255040	A1	20051117	US 2005-157119	20050620
ZA 2005006515	A	20060628	ZA 2005-6515	20050815
KR 2006002770	A	20060109	KR 2005-715424	20050819
MX 2005008926	A	20051005	MX 2005-8926	20050822
IN 2005KN01718	A	20070323	IN 2005-KN1718	20050829
NO 2005004052	A	20051021	NO 2005-4052	20050831
HK 1083627	A1	20080613	HK 2006-105675	20060516
US 20060247270	A1	20061102	US 2006-458231	20060718
US 7425561	B2	20080916		
US 20080138287	A1	20080612	US 2008-26847	20080206
PRIORITY APPLN. INFO.:			US 1998-210113	A1 19981211
			US 2002-162129	A2 20020604
			US 2003-372642	A 20030221
			CN 2004-80004736	A3 20040220
			NZ 2004-541794	A3 20040220
			WO 2004-US5044	A 20040220
			US 2005-157119	A1 20050620
			US 2006-458231	A3 20060718

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:77298

GI



AB The present invention relates to 3-substituted-2-(arylalkyl)-1-azabicycloalkanes I [A1 = (CH2)_n; A2 = (CH2)_m; A3 = (CH2)_p; m, n = 1, 2; p = 1 - 4; X = O, NR'; Z = NR', covalent bond, A; A = CR'R'', CR'R''CR'R'', CR':CR', C.tplbond.C (wherein, when Z = bond or A, X = N); Ar = (un)substituted carbocyclic, heterocyclic monocyclic or fused polycyclic aryl; Cy = (un)substituted 5- or 6-membered heteroarom. ring; wavy lines = relative or absolute stereochem. (cis or trans, R or S); R', R'' = H, (un)branched C1-8-alkyl, C3-8-cycloalkyl, heterocyclyl, aryl, arylalkyl {wherein, substituents = alkyl, alkenyl, heterocyclyl, cycloalkyl, (un)substituted aryl, (un)substituted arylalkyl, F, Cl, Br, I, OR', NR'R'', CF3, CN, NO2, C.tplbond.CR', SR', N3, C(:O)NR'R'', NR'C(:O)R'', C(:O)R', C(:O)OR', OC(:O)R', O(CR'R'')rC(:O)R', O(CR'R'')rNR'C(:O)R', O(CR'R'')rNR'SO2R', OC(:O)NR'R'', NR'C(:O)OR'', SO2R', SO2NR'R'', NR'SO2R''}; R'R'' = ring; r = 1 - 6] and II, methods of preparing the compds. and methods of treatment using the compds. The azabicycloalkanes generally are azabicycloheptanes, azabicyclooctanes, or azabicyclononanes. The aryl group in the arylalkyl moiety is a 5- or 6-membered ring

heteroarom., preferably 3-pyridinyl and 5-pyrimidinyl moieties, and the alkyl group is typically a C 1-4 alkyl. The substituent at the 3-position of the 1-azabicycloalkane is a carbonyl group-containing moiety, such as an amide, carbamate, urea, thioamide, thiocarbamate, thiourea or similar functionality. The compds. exhibit activity at nicotinic acetylcholine receptors (nAChRs), particularly the $\alpha 7$ nAChR subtype, and are useful towards modulating neurotransmission and the release of ligands involved in neurotransmission. Methods for preventing or treating conditions and disorders, including central nervous system (CNS) disorders, which are characterized by an alteration in normal neurotransmission, are also disclosed. Also disclosed are methods for treating inflammation, autoimmune disorders, pain and excess neovascularization, such as that associated with tumor growth.


IT 639494-67-0P

RL: PAC (Pharmacological activity); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-substituted-2(arylalkyl)-1-azabicycloalkanes exhibiting activity at nicotinic acetylcholine receptors)

RN 639494-67-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)



IT	639489-64-8P	639489-66-0P	639489-68-2P
	639489-70-6P	639489-80-8P	639489-82-0P
	639489-84-2P	639489-86-4P	639489-96-6P
	639489-98-8P	639490-00-9P	639490-02-1P
	639490-04-3P	639490-06-5P	639490-08-7P
	639490-10-1P	639490-12-3P	639490-14-5P
	639490-16-7P	639490-18-9P	639490-21-4P
	639490-23-6P	639490-25-8P	639490-27-0P
	639490-29-2P	639490-31-6P	639490-33-8P
	639490-35-0P	639490-37-2P	639490-40-7P
	639490-43-0P	639490-45-2P	639490-47-4P
	639490-49-6P	639490-51-0P	639490-53-2P
	639490-55-4P	639490-57-6P	639490-59-8P
	639490-61-2P	639490-72-5P	639490-74-7P
	639490-76-9P	639490-78-1P	


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 3-substituted-2(arylalkyl)-1-azabicycloalkanes exhibiting activity at nicotinic acetylcholine receptors)

RN 639489-64-8 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-66-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-68-2 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-70-6 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-80-8 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-82-0 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-84-2 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-86-4 CAPLUS

CN 2-Benzofurancarboxamide, N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-96-6 CAPLUS

CN 2-Benzofurancarboxamide, 3-methyl-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639489-98-8 CAPLUS

CN 2-Benzofurancarboxamide, 3-methyl-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-00-9 CAPLUS

CN 2-Benzofurancarboxamide, 3-methyl-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-02-1 CAPLUS

CN 2-Benzofurancarboxamide, 3-methyl-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-04-3 CAPLUS

CN 2-Benzofurancarboxamide, 5-nitro-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-06-5 CAPLUS

CN 2-Benzofurancarboxamide, 5-nitro-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-08-7 CAPLUS

CN 2-Benzofurancarboxamide, 5-nitro-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-10-1 CAPLUS

CN 2-Benzofurancarboxamide, 5-nitro-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-12-3 CAPLUS

CN 2-Benzofurancarboxamide, 5-methoxy-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-14-5 CAPLUS

CN 2-Benzofurancarboxamide, 5-methoxy-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-16-7 CAPLUS

CN 2-Benzofurancarboxamide, 5-methoxy-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-18-9 CAPLUS

CN 2-Benzofurancarboxamide, 5-methoxy-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-21-4 CAPLUS

CN 2-Benzofurancarboxamide, 7-methoxy-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-23-6 CAPLUS

CN 2-Benzofurancarboxamide, 7-methoxy-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-25-8 CAPLUS

CN 2-Benzofurancarboxamide, 7-methoxy-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-27-0 CAPLUS

CN 2-Benzofurancarboxamide, 7-methoxy-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-29-2 CAPLUS

CN 2-Benzofurancarboxamide, 7-ethoxy-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-31-6 CAPLUS

CN 2-Benzofurancarboxamide, 7-ethoxy-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-33-8 CAPLUS

CN 2-Benzofurancarboxamide, 7-ethoxy-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-35-0 CAPLUS

CN 2-Benzofurancarboxamide, 7-ethoxy-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-37-2 CAPLUS

CN 2-Benzofurancarboxamide, 5-chloro-3-methyl-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-40-7 CAPLUS

CN 2-Benzofurancarboxamide, 5-chloro-3-methyl-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-43-0 CAPLUS

CN 2-Benzofurancarboxamide, 5-chloro-3-methyl-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-45-2 CAPLUS

CN 2-Benzofurancarboxamide, 5-chloro-3-methyl-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-47-4 CAPLUS

CN 2-Benzofurancarboxamide, 6-bromo-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-49-6 CAPLUS

CN 2-Benzofurancarboxamide, 6-bromo-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-51-0 CAPLUS

CN 2-Benzofurancarboxamide, 6-bromo-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-53-2 CAPLUS

CN 2-Benzofurancarboxamide, 6-bromo-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-55-4 CAPLUS

CN 2-Benzofurancarboxamide, 4-acetyl-7-methoxy-N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-57-6 CAPLUS

CN 2-Benzofurancarboxamide, 4-acetyl-7-methoxy-N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-59-8 CAPLUS

CN 2-Benzofurancarboxamide, 4-acetyl-7-methoxy-N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-61-2 CAPLUS

CN 2-Benzofurancarboxamide, 4-acetyl-7-methoxy-N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 639490-72-5 CAPLUS

CN Naphtho[2,1-b]furan-2-carboxamide,
N-[(2R,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX
NAME)


Absolute stereochemistry.



RN 639490-74-7 CAPLUS


CN Naphtho[2,1-b]furan-2-carboxamide,
N-[(2R,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX
NAME)

Absolute stereochemistry.




RN 639490-76-9 CAPLUS
CN Naphtho[2,1-b]furan-2-carboxamide,
N-[(2S,3R)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX
NAME)

Absolute stereochemistry.



RN 639490-78-1 CAPLUS
CN Naphtho[2,1-b]furan-2-carboxamide,
N-[(2S,3S)-2-(3-pyridinylmethyl)-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX
NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 9 THERE ARE 9 CAPLUS RECORDS THAT CITE THIS RECORD
(11 CITINGS)
REFERENCE COUNT: 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 21 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN
ACCESSION NUMBER: 2003:991508 CAPLUS
DOCUMENT NUMBER: 140:42022
TITLE: Preparation of 2-heteroaryl carboxamides for the
treatment and/or the prophylaxis of diseases effecting
memory
INVENTOR(S): Luithle, Joachim; Boess, Frank-Gerhard; Erb,
Christina; Hafner, Frank-Thorsten; Schnizler, Katrin;
Flessner, Timo; Van Kampen, Marja; Van Der Staay,
Franz-Josef
PATENT ASSIGNEE(S): Bayer Healthcare A.-G., Germany
SOURCE: PCT Int. Appl., 239 pp.

DOCUMENT TYPE: Patent
 LANGUAGE: German
 FAMILY ACC. NUM. COUNT: 1
 PATENT INFORMATION:




CODEN: PIXXD2

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003104227	A1	20031218	WO 2003-EP5735	20030602
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
DE 10257078	A1	20040624	DE 2002-10257078	20021206
DE 10257537	A1	20040701	DE 2002-10257537	20021210
DE 10305922	A1	20040304	DE 2003-10305922	20030213
CA 2488761	A1	20031218	CA 2003-2488761	20030602
AU 2003238450	A1	20031222	AU 2003-238450	20030602
EP 1515967	A1	20050323	EP 2003-732517	20030602
EP 1515967	B1	20061102		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003012446	A	20050419	BR 2003-12446	20030602
CN 1675204	A	20050928	CN 2003-818851	20030602
JP 2005533052	T	20051104	JP 2004-511297	20030602
AT 344262	T	20061115	AT 2003-732517	20030602
ES 2276072	T3	20070616	ES 2003-732517	20030602
ZA 2004009883	A	20060222	ZA 2004-9883	20041207
MX 2004012439	A	20050419	MX 2004-12439	20041209
NO 2005000063	A	20050106	NO 2005-63	20050106
US 20060160877	A1	20060720	US 2006-516777	20060113
PRIORITY APPLN. INFO.:				
			DE 2002-10225536	A 20020610
			DE 2002-10257078	A 20021206
			DE 2002-10257537	A 20021210
			DE 2003-10305922	A 20030213
			WO 2003-EP5735	W 20030602

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT

OTHER SOURCE(S): MARPAT 140:42022


GI



AB The invention relates to the novel 2-heteroaryl carboxamides I [R1 = 1-azabicyclo[2.2.2]oct-3-yl, (optionally replaced via the nitrogen atom by a group selected from the family C1-4-alkyl, benzyl and oxy); R2 = H, C1-6-alkyl; R3 = H, halogen, C1-6-alkyl; R4 = H, halogen, CN, NH2, CF3, OCF3, C1-6-alkyl, C1-6-alkylcarbonyl, C1-6-alkylamino, CHO, CO2H, C1-6-alkoxy, C1-6-alkoxycarbonyl, C1-6-alkylthio, C1-6-alkylcarbonylamino, C1-6-alkylaminocarbonyl, C1-4-alkylsulfonylamino, C3-8-cycloalkylcarbonylamino, C3-6-cycloalkylaminocarbonyl, pyrrolyl, C1-6-alkylaminocarbonyl, heterocyclylcarbonyl, heterocyclylcarbonylamino, heteroarylcarbonylamino, OH, Ph, heterocyclyl; A = O, S; the ring B = benzo or pyrido (optionally replaced by the groups from the family of halogen, cyano, formyl, trifluoromethyl, trifluoromethoxy, nitro, amino, C1-6-alkyl and C1-6-alkoxy); E = C:C, aryl and heteroaryl, (wherein aryl and heteroaryl may be replaced by groups from the family of halogen, cyano, trifluoromethyl, trifluoromethoxy, nitro, amino, C1-6-alkoxy and C1-6-alkyl)] and to the solvates, salts or solvates of salts of said compds. Thus, carboxamide II was prepared from carboxamide III via coupling with 2-(HOCH2)C6H4B(OH)2 in aqueous DMF containing NaOH and catalytic [1,1'-bis(diphenylphosphino)ferrocene]palladium(II) chloride. The invention also relates to the use of said compds. in the production of drugs for and treatment and/or the prophylaxis of diseases for improving perception, power of concentration, learning power and/or retentiveness of memory. The affinity of I for 7 α -nicotinic acetylcholine receptor (via inhibition of [3H]Methyllycaconitine binding in rat brain membranes) was determined [Ki = 1.6 nM {I·HCl; R1 = (R)-1-azabicyclo[2.2.2]oct-3-yl, R2 = R3 = H, A = S, B = benzo; 7-ER4 = 4-(hydroxymethyl)phenyl}; Ki = <1 nM {I·2HCl; R1 = (R)-1-azabicyclo[2.2.2]oct-3-yl, R2 = R3 = H, A = S, B = benzo; 7-ER4 = 2-(aminomethyl)phenyl}; Ki = <0.1 nM {I·HCl; R1 = (R)-1-azabicyclo[2.2.2]oct-3-yl, R2 = R3 = H, A = S, B = benzo; 7-ER4 = 3-carboxyphenyl}; Ki = 3 nM {I·HCl; R1 = (R)-1-azabicyclo[2.2.2]oct-3-yl; R2 = R3 = H, A = O, B = benzo; 7-ER4 = 3-(cyclopropylaminocarbonyl)phenyl}].

IT 634903-28-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and N-acylation of; preparation of 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of diseases effecting memory and perception)
 RN 634903-28-9 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 7-(3-aminophenyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 634904-39-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and N-oxidation or acid addition salt formation of; preparation of 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of diseases effecting memory and perception)
 RN 634904-39-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)- (CA INDEX NAME)

Absolute stereochemistry.



IT 634904-11-3P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and O-demethylation, N-alkylation or free base formation of; preparation of 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of diseases effecting memory and perception)

RN 634904-11-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 634903-83-6P 634904-58-8P 634904-62-4P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation and amidation of; preparation of 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of diseases effecting memory and perception)

RN 634903-83-6 CAPLUS

CN Benzoic acid, 3-[2-[[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]benzo[b]thien-7-yl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-58-8 CAPLUS

CN Benzoic acid, 3-[2-[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]-7-benzofuranyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-62-4 CAPLUS

CN Benzoic acid, 3-[2-[[(3S)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]-7-benzofuranyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

IT 634903-81-4P 634904-40-8P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and carbamylation of, with isocyanates; preparation of 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of diseases effecting memory and perception)

RN 634903-81-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, 7-[2-(aminomethyl)phenyl]-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 634904-40-8 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-(aminomethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

IT 634904-61-3P 634904-89-5P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and carbamylation of; preparation of 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of diseases effecting memory and perception)
 RN 634904-61-3 CAPLUS
 CN 2-Benzofurancarboxamide, 7-[2-(aminomethyl)phenyl]-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 634904-89-5 CAPLUS
 CN 2-Benzofurancarboxamide, 7-[2-(aminomethyl)phenyl]-N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


IT 634904-23-7P 634904-41-9P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (preparation and carbamylation or N-acylation of; preparation of 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of diseases effecting memory and perception)
 RN 634904-23-7 CAPLUS
 CN 2-Benzofurancarboxamide, 7-(3-aminophenyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)

Absolute stereochemistry.




RN 634904-41-9 CAPLUS
 CN 2-Benzofurancarboxamide, 7-(2-aminophenyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)

Absolute stereochemistry.



IT 550998-72-6P 550998-99-7P 550999-06-9P
 550999-27-4P 550999-37-6P 550999-43-4P
 634905-17-2P 634905-19-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and coupling reactions of, with boronates; preparation of
 2-heteroaryl carboxamides for the treatment and/or the prophylaxis of
 diseases effecting memory and perception)
 RN 550998-72-6 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-
 bromo-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550998-99-7 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-
 bromo-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-06-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-bromo-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-27-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo-5-
 fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-37-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-bromo- (CA
 INDEX NAME)


Absolute stereochemistry.



RN 550999-43-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-bromo-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634905-17-2 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634905-19-4 CAPLUS


CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo- (CA INDEX NAME)

Absolute stereochemistry. Rotation (-).




IT 550999-35-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and coupling reactions of; preparation of 2-heteroaryl
 carboxamides
 for the treatment and/or the prophylaxis of diseases effecting memory
 and perception)
 RN 550999-35-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo- (CA
 INDEX NAME)

Absolute stereochemistry. Rotation (+).



IT 551938-28-4P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
 (Reactant or reagent)
 (preparation and cyclocondensation reactions of; preparation of 2-heteroaryl
 carboxamides for the treatment and/or the prophylaxis of diseases
 effecting memory and perception)
 RN 551938-28-4 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
 [(hydroxyamino)iminomethyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.



● 2 HCl

IT 550999-96-7P
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT


(Reactant or reagent)

(preparation and reaction or, with hydroxylamine; preparation of
2-heteroaryl
carboxamides for the treatment and/or the prophylaxis of diseases
effecting memory and perception)

RN 550999-96-7 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
cyano-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT 634905-18-3P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation and reductive amination of, with morpholine; preparation of
2-heteroaryl carboxamides for the treatment and/or the prophylaxis of
diseases effecting memory and perception)

RN 634905-18-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(4-
formylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT	634903-05-2P	634903-07-4P	634903-10-9P
	634903-11-0P	634903-12-1P	634903-13-2P
	634903-14-3P	634903-15-4P	634903-16-5P
	634903-17-6P	634903-18-7P	634903-19-8P
	634903-20-1P	634903-21-2P	634903-22-3P
	634903-23-4P	634903-24-5P	634903-25-6P
	634903-26-7P	634903-27-8P	634903-29-0P
	634903-30-3P	634903-31-4P	634903-32-5P

634903-33-6P	634903-34-7P	634903-35-8P
634903-36-9P	634903-37-0P	634903-38-1P
634903-39-2P	634903-40-5P	634903-41-6P
634903-42-7P	634903-43-8P	634903-44-9P
634903-45-0P	634903-46-1P	634903-47-2P
634903-48-3P	634903-49-4P	634903-50-7P
634903-51-8P	634903-52-9P	634903-53-0P
634903-54-1P	634903-55-2P	634903-56-3P
634903-57-4P	634903-58-5P	634903-59-6P
634903-60-9P	634903-61-0P	634903-62-1P
634903-63-2P	634903-64-3P	634903-65-4P
634903-67-6P	634903-68-7P	634903-69-8P
634903-70-1P	634903-71-2P	634903-72-3P
634903-73-4P	634903-74-5P	634903-75-6P
634903-76-7P	634903-77-8P	634903-78-9P
634903-79-0P	634903-80-3P	634903-82-5P
634903-84-7P	634903-85-8P	634903-86-9P
634903-87-0P	634903-88-1P	634903-89-2P
634903-90-5P	634903-91-6P	634903-92-7P
634903-93-8P	634903-94-9P	634903-95-0P
634903-96-1P	634903-97-2P	634903-98-3P
634903-99-4P	634904-00-0P	634904-01-1P
634904-02-2P	634904-03-3P	634904-06-6P
634904-07-7P	634904-08-8P	634904-09-9P
634904-10-2P	634904-12-4P	634904-13-5P
634904-14-6P	634904-15-7P	634904-16-8P
634904-17-9P	634904-18-0P	634904-19-1P
634904-20-4P	634904-21-5P	634904-22-6P
634904-24-8P	634904-25-9P	634904-26-0P
634904-27-1P	634904-28-2P	634904-29-3P
634904-30-6P	634904-31-7P	634904-32-8P
634904-33-9P	634904-34-0P	634904-35-1P
634904-36-2P	634904-37-3P	634904-38-4P
634904-39-5DP, free base, salt and/or solvate		
634904-42-0P	634904-43-1P	634904-44-2P
634904-45-3P	634904-46-4P	634904-47-5P
634904-48-6P	634904-49-7P	634904-50-0P
634904-51-1P	634904-52-2P	634904-53-3P
634904-54-4P	634904-55-5P	634904-56-6P
634904-57-7P	634904-59-9P	634904-60-2P
634904-63-5P	634904-64-6P	634904-65-7P
634904-66-8P	634904-67-9P	634904-68-0P
634904-69-1P	634904-70-4P	634904-71-5P
634904-72-6P	634904-74-8P	634904-75-9P
634904-76-0P	634904-78-2P	634904-80-6P
634904-82-8P	634904-84-0P	634904-85-1P
634904-87-3P	634904-88-4P	634904-90-8P
634904-91-9P	634904-92-0P	634904-93-1P
634904-94-2P	634904-95-3P	634904-96-4P
634904-97-5P	634904-98-6P	634904-99-7P
634905-00-3P	634905-01-4P	634905-02-5P
634905-03-6P	634905-04-7P	634905-05-8P
634905-06-9P	634905-08-1P	634905-22-9DP,
free base, salt and/or solvate		
634905-23-0DP, free base, salt and/or solvate		
634905-24-1DP, free base, salt and/or solvate		
634905-25-2DP, free base, salt and/or solvate		
634905-26-3DP, free base, salt and/or solvate		
634905-27-4DP, free base, salt and/or solvate		

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)


(preparation of 2-heteroaryl carboxamides for the treatment and/or the

prophylaxis of diseases effecting memory and perception)

RN 634903-05-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[2-(hydroxymethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-07-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[3-(hydroxymethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-10-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[4-(hydroxymethyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-11-0 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[4-(4-morpholinyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-12-1 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(4-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-13-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(3-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-14-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-15-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-16-5 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[4-(3-hydroxy-1-propyn-1-yl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-17-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro-7-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-18-7 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro-7-[4-(trifluoromethoxy)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-19-8 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-phenyl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-20-1 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-phenyl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-21-2 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(3-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-22-3 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(3-hydroxy-1-propyn-1-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634903-23-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-phenyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-24-5 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-25-6 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-26-7 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-27-8 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-29-0 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(4-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-30-3 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 7-(4-acetylphenyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-31-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(4-formylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-32-5 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(1-oxopropyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-33-6 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-formylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-34-7 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(1-oxopropyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-35-8 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 7-(3-acetylphenyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-36-9 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(methylthio)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-37-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-thienyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-38-1 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(trifluoromethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-39-2 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(4-fluorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-40-5 CAPLUS
 CN 1H-Pyrrole-1-carboxylic acid, 2-[2-[[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]benzo[b]thien-7-yl]-, 1,1-dimethylethyl ester, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-41-6 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-cyanophenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-42-7 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(4-cyanophenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-43-8 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2,4-difluorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-44-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2,5-difluorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-45-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-(methythio)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-46-1 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-fluorophenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-47-2 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(methylthio)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-48-3 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-furanyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-49-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-ethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-50-7 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2,4-dimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-51-8 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, 7-(2-acetylphenyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-52-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2,5-dimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-53-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(5-fluoro-2-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-54-1 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(4-methoxy-2-methylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-55-2 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(5-fluoro-2-methylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-56-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-formylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-57-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-formyl-3-phenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-58-5 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, 7-[3-(acetylamino)phenyl]-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-59-6 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[4-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-60-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(5-methyl-1,2,4-oxadiazol-3-yl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-61-0 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[2-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-62-1 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(5-phenyl-1,2,4-oxadiazol-3-yl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-63-2 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[5-(phenylmethyl)-1,2,4-oxadiazol-3-yl]-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-64-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[4-(4-morpholinylmethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 634903-65-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(dimethylamino)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-67-6 CAPLUS
 CN Formic acid, compd. with N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-thienyl)benzo[b]thiophene-2-carboxamide (1:1) (CA INDEX NAME)

CM 1

CRN 634903-66-5
 CMF C20 H20 N2 O S2

Absolute stereochemistry.




CM 2

CRN 64-18-6
 CMF C H2 O2

O=CH-OH

RN 634903-68-7 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 7-(5-acetyl-2-thienyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-69-8 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(6-oxo-2-piperidiny)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-70-1 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-71-2 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-72-3 CAPLUS

CN Carbamic acid, ethyl-, [2-[2-[[3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]benzo[b]thien-7-yl]phenyl]methyl ester, monohydrochloride (9CI) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-73-4 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[[[(methylamino)carbonyl]oxy]methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-74-5 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(2-oxo-1-pyrrolidinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-75-6 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(1-piperazinyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 634903-76-7 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(3-oxo-4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-77-8 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(1-pyrrolidinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-78-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-79-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(1-pyrrolidinyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 634903-80-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(4-morpholinylcarbonyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-82-5 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(2,2-dimethyl-1-oxopropyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-84-7 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[[[(methylamino)carbonyl]amino]methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-85-8 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(1H-pyrrol-1-yl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-86-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(4-morpholinylcarbonyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-87-0 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-88-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-89-2 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [(2-methoxyacetyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 634903-90-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(2-oxo-1-
 pyrrolidinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




RN 634903-91-6 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 7-[3-(acetylamino)phenyl]-N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



RN 634903-92-7 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-93-8 CAPLUS
 CN Benzoic acid, 4-[2-[[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]-7-benzofuranyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634903-94-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[3-(trifluoromethoxy)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-95-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-96-1 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-97-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(3-oxo-4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-98-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634903-99-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-00-0 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[4-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-01-1 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[4-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-02-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[3-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-03-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[4-(dimethylamino)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-06-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(4-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-07-7 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(3-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-08-8 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(4-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-09-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-10-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-12-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(4-methoxy-3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-13-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(4-morpholinylcarbonyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-14-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(1-piperidinyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 634904-15-7 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-pyridinyl)-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl

RN 634904-16-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [[methylamino]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 634904-17-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [[ethylamino]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 634904-18-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-19-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[[(1,1-dimethylethyl)amino]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-20-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(methanesulfonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-21-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-(cyclobutylcarbonyl)amino]phenyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-22-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(2-pyrimidinyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-24-8 CAPLUS

CN 2-Benzofurancarboxamide, 7-[3-(acetamido)phenyl]-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-25-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [(cyclopropylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-26-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(2-
 methoxyacetyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-27-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [(cyclobutylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-28-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-
 [(cyclopropylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-29-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[(2-methoxyacetyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-30-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-31-7 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-32-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-pyridinyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-33-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-(4-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-34-0 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-(3-methoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-35-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[[[(1-methylethyl)amino]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-36-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[[[(ethylamino)carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-37-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-
 [(methylamino)carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA INDEX
 NAME)


Absolute stereochemistry.



● HCl

RN 634904-38-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[[[1,1-
 dimethylethyl]amino]carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA
 INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-39-5 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634904-42-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(4-morpholinylcarbonyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-43-1 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(4-morpholinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-44-2 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(cyclopropylamino)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-45-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(ethylmethylamino)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-46-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(2,5-dihydro-1H-pyrrol-1-yl)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-47-5 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[(3-methoxypropyl)amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-48-6 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[(2-methoxyethyl)methylamino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-49-7 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[(3-ethoxypropyl)amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-50-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 634904-51-1 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(cyclobutylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-52-2 CAPLUS

CN 5-Isioxazolecarboxamide, N-[3-[2-[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]benzo[b]thien-7-yl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-53-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(cyclopentylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-54-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(cyclohexylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-55-5 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [(tetrahydro-2-furanyl)carbonyl]amino]phenyl]-, hydrochloride (1:1) (CA
 INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-56-6 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [(2-methyl-1-oxopropyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX
 NAME)

Absolute stereochemistry.




● HCl

RN 634904-57-7 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(2-furanylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-59-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-(hydroxymethyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-60-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2,5-dimethoxyphenyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-63-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(cyclopropylamino)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-64-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(ethylmethylamino)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-65-7 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(butylamino)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-66-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[2-methylpropyl)amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-67-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(1-piperidinylcarbonyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-68-0 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-69-1 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[[3-methoxypropyl]amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-70-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[2-methoxyethyl)methylamino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-71-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[3-ethoxypropyl)amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-72-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 634904-74-8 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(ethylmethylamino)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-75-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
 [(butylamino)carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-76-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[2-
 methylpropyl)amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-78-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(1-piperidinylcarbonyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-80-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[[2-(dimethylamino)ethyl]amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-82-8 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[3-methoxypropyl)amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-84-0 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[[2-methoxyethyl)methylamino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-85-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(3-ethoxypropyl)amino]carbonyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-87-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(4-methyl-1-piperazinyl)carbonyl]phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 634904-88-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-(1-pyrrolidinyl)phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634904-90-8 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[[[(methylamino)carbonyl]amino]methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-91-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-[[[(methylamino)carbonyl]amino]methyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-92-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(2,2-dimethyl-1-oxopropyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-93-1 CAPLUS
 CN 5-Isioxazolecaboxamide, N-[3-[2-[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]-7-benzofuranyl]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-94-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(cyclopentylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-95-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(2-methyl-1-oxopropyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 634904-96-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-[(2-furanylcarbonyl)amino]phenyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 634904-97-5 CAPLUS


CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, acetate (1:1) (CA INDEX NAME)

CM 1

CRN 634904-39-5

CMF C23 H24 N2 O3


Absolute stereochemistry.



CM 2

CRN 64-19-7

CMF C2 H4 O2




RN 634904-98-6 CAPLUS
CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, 4-methylbenzenesulfonate (1:1) (CA INDEX NAME)

CM 1


CRN 634904-39-5
CMF C23 H24 N2 O3

Absolute stereochemistry.



CM 2

CRN 104-15-4
CMF C7 H8 O3 S




RN 634904-99-7 CAPLUS
CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, (2E)-2-butenedioate (1:1) (CA INDEX NAME)

CM 1

CRN 634904-39-5
CMF C23 H24 N2 O3

Absolute stereochemistry.




CM 2

CRN 110-17-8

CMF C4 H4 O4

Double bond geometry as shown.



RN 634905-00-3 CAPLUS


CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-methoxyphenyl)-, ethanedioate (1:1) (CA INDEX NAME)

CM 1

CRN 634904-39-5

CMF C23 H24 N2 O3


Absolute stereochemistry.



CM 2

CRN 144-62-7


CMF C2 H2 O4



RN 634905-01-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(2-hydroxyphenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-02-5 CAPLUS

CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[7-(2-methoxyphenyl)-2-benzofuranyl]carbonyl]amino]-1-methyl-, chloride (1:1), (3R)- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-03-6 CAPLUS


CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[7-(2-methoxyphenyl)-2-benzofuranyl]carbonyl]amino]-1-(phenylmethyl)-, bromide (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.




RN 634905-04-7 CAPLUS
CN 1-Azoniabicyclo[2.2.2]octane, 3-[[[7-(2-methoxyphenyl)-2-benzofuranyl]carbonyl]methylamino]-1-methyl-, chloride (1:1), (3R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 634905-05-8 CAPLUS
CN 2-Benzofurancarboxamide, 7-(2-methoxyphenyl)-N-[(3R)-1-oxido-1-azabicyclo[2.2.2]oct-3-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-06-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[3-(4-morpholinylmethyl)phenyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 634905-08-1 CAPLUS

CN 2-Benzofurancarboxamide, 7-(5-acetyl-2-thienyl)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 634905-22-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[4-(3-oxo-4-morpholinyl)phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-23-0 CAPLUS

CN Benzoic acid, 3-[2-[[(3R)-1-azabicyclo[2.2.2]oct-3-ylamino]carbonyl]benzo[b]thien-7-yl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-24-1 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
[(cyclopropylcarbonyl)amino]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-25-2 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, 7-[2-(aminomethyl)phenyl]-N-(3R)-1-
azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-26-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[2-
[[[(methylamino)carbonyl]amino]methyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 634905-27-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[3-
[[[(ethylamino)carbonyl]amino]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 634905-20-7P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT
(Reactant or reagent)

(preparation of 2-heteroaryl carboxamides for the treatment and/or the
prophylaxis of diseases effecting memory and perception)

RN 634905-20-7 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(3-
formylphenyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 22 OF 22 CAPLUS COPYRIGHT 2010 ACS on STN

ACCESSION NUMBER: 2003:532663 CAPLUS

DOCUMENT NUMBER: 139:69412

TITLE: Preparation of 2-heteroarylcarboxylic acid amides for
therapeutic use as nicotinic acetylcholine receptor
agonists

INVENTOR(S): Hendrix, Martin; Boess, Frank-Gerhard; Erb, Christina;
Flessner, Timo; Van Kampen, Marja; Luithle, Joachim;
Methfessel, Christoph; Wiese, Welf Burkhard

PATENT ASSIGNEE(S): Bayer Aktiengesellschaft, Germany

SOURCE: PCT Int. Appl., 164 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: German

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003055878	A1	20030710	WO 2002-EP14288	20021216
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
DE 10164139	A1	20030710	DE 2001-10164139	20011227
CA 2471593	A1	20030710	CA 2002-2471593	20021216
AU 2002358718	A1	20030715	AU 2002-358718	20021216
EP 1461335	A1	20040929	EP 2002-793023	20021216
EP 1461335	B1	20070228		
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK			
ES 2282503	T3	20071016	ES 2002-793023	20021216
US 20050119325	A1	20050602	US 2005-500096	20050111

PRIORITY APPLN. INFO.:

DE 2001-10164139

A 20011227



WO 2002-EP14288

W 20021216

OTHER SOURCE(S):

MARPAT 139:69412

GI



AB N-quinuclidinyl-2-heteroarylcarboxylic acid amides, such as I [R = 2-heteroaryl], were prepared for pharmaceutical use as nicotinic acetylcholine receptor (nAChR) agonists for the treatment of cognition, learning and memory disorders. Thus, the hydrochloride salt of amide II was prep'd in 62.1% yield by an amidation reaction of 6-nitrobenzothiophene-2-carboxylic acid with (R)-3-aminoquinuclidine dihydrochloride using HATU and DIPEA in DMF. The prepared amides were assayed for $\alpha 7$ -nAChR binding activity using rat brain hippocampus tissue.

IT 550998-69-1P 550998-81-7P 550998-86-2P
 550999-12-7P 550999-17-2P 550999-18-3P
 550999-21-8P 550999-23-0P 550999-37-6P
 550999-43-4P 550999-48-9P 550999-59-2P
 550999-62-7P 550999-69-4P 550999-72-9P
 550999-80-9P 550999-96-7P 551000-07-8P
 551000-11-4P 551000-16-9P


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)

(preparation of N-quinuclidinyl-2-heteroarylcarboxamides as $\alpha 7$ nicotinic acetylcholine receptor agonists for therapeutic use in the treatment of cognition, learning and memory disorders)

RN 550998-69-1 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-nitro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550998-81-7 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 550998-86-2 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 5-amino-N-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:2) (CA INDEX NAME)



● 2 HCl

RN 550999-12-7 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-17-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 550999-18-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 550999-21-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 550999-23-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-nitro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-37-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-bromo- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-43-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-bromo-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-48-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-59-2 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, 5-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



● 2 HCl


RN 550999-62-7 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-nitro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-69-4 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-methyl-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-72-9 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-bromo-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-80-9 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 6-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 550999-96-7 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-cyano-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 551000-07-8 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-chloro-6-nitro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 551000-11-4 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-cyano-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 551000-16-9 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 6-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

IT	550998-70-4P	550998-71-5P	550998-72-6P
	550998-73-7P	550998-74-8P	550998-75-9P
	550998-76-0P	550998-77-1P	550998-78-2P
	550998-79-3P	550998-82-8P	550998-83-9P
	550998-84-0P	550998-85-1P	550998-87-3P
	550998-90-8P	550998-91-9P	550998-92-0P
	550998-93-1P	550998-94-2P	550998-95-3P

550998-96-4P	550998-97-5P	550998-98-6P
550998-99-7P	550999-00-3P	550999-01-4P
550999-02-5P	550999-03-6P	550999-04-7P
550999-05-8P	550999-06-9P	550999-07-0P
550999-08-1P	550999-09-2P	550999-10-5P
550999-11-6P	550999-13-8P	550999-14-9P
550999-15-0P	550999-16-1P	550999-19-4P
550999-20-7P	550999-22-9P	550999-24-1P
550999-25-2P	550999-26-3P	550999-27-4P
550999-28-5P	550999-29-6P	550999-30-9P
550999-31-0P	550999-32-1P	550999-33-2P
550999-34-3P	550999-35-4P	550999-36-5P
550999-38-7P	550999-39-8P	550999-40-1P
550999-41-2P	550999-42-3P	550999-44-5P
550999-45-6P	550999-46-7P	550999-47-8P
550999-49-0P	550999-50-3P	550999-51-4P
550999-52-5P	550999-53-6P	550999-55-8P
550999-56-9P	550999-57-0P	550999-58-1P
550999-60-5P	550999-61-6P	550999-63-8P
550999-64-9P	550999-65-0P	550999-66-1P
550999-67-2P	550999-68-3P	550999-70-7P
550999-71-8P	550999-73-0P	550999-74-1P
550999-75-2P	550999-76-3P	550999-77-4P
550999-78-5P	550999-79-6P	550999-81-0P
550999-82-1P	550999-83-2P	550999-84-3P
550999-85-4P	550999-86-5P	550999-87-6P
550999-88-7P	550999-89-8P	550999-90-1P
550999-91-2P	550999-92-3P	550999-93-4P
550999-94-5P	550999-95-6P	550999-97-8P
550999-98-9P	550999-99-0P	551000-00-1P
551000-01-2P	551000-02-3P	551000-03-4P
551000-04-5P	551000-05-6P	551000-06-7P
551000-08-9P	551000-09-0P	551000-10-3P
551000-12-5P	551000-13-6P	551000-14-7P
551000-15-8P	551000-17-0P	551000-18-1P
551000-19-2P	551000-20-5P	551000-21-6P
551938-28-4P	551938-29-5P	551938-30-8P
551938-31-9P		


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of N-quinuclidinyl-2-heteroarylcarboxamides as $\alpha 7$ nicotinic acetylcholine receptor agonists for therapeutic use in the treatment of cognition, learning and memory disorders)

RN 550998-70-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-nitro- (CA INDEX NAME)

Absolute stereochemistry.




RN 550998-71-5 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-

chloro-6-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 550998-72-6 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-bromo-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550998-73-7 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-bromo- (CA INDEX NAME)


Absolute stereochemistry.



RN 550998-74-8 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-bromo-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550998-75-9 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-fluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550998-76-0 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550998-77-1 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-methyl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550998-78-2 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 550998-79-3 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-methyl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550998-82-8 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-5-nitro- (CA INDEX NAME)



RN 550998-83-9 CAPLUS


CN Benzo[b]thiophene-2-carboxamide, 5-amino-N-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 550998-84-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, 5-amino-N-1-azabicyclo[2.2.2]oct-3-yl-, (CA INDEX NAME)



RN 550998-85-1 CAPLUS


CN Benzo[b]thiophene-2-carboxamide, 5-(acetylamino)-N-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 550998-87-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, 5-(acetylamino)-N-1-azabicyclo[2.2.2]oct-3-yl-, (CA INDEX NAME)



RN 550998-90-8 CAPLUS


CN Benzo[b]thiophene-2-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 550998-91-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX
NAME)



RN 550998-92-0 CAPLUS


CN Benzo[b]thiophene-2-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-3-chloro-,
hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 550998-93-1 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-3-chloro-
(CA INDEX NAME)



RN 550998-94-2 CAPLUS


CN Benzo[b]thiophene-2-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-7-bromo-, hydrochloride (1:1) (CA INDEX NAME)



● HCl


RN 550998-95-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-7-bromo-, (CA INDEX NAME)



RN 550998-96-4 CAPLUS


CN 2-Benzofurancarboxamide, N-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)



● HCl

RN 550998-97-5 CAPLUS


CN 2-Benzofurancarboxamide, N-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)



RN 550998-98-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550998-99-7 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-00-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-01-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-
 (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-02-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-03-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5,7-dichloro-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-04-7 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5,7-dichloro-
 (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-05-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5,7-dichloro-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-06-9 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-bromo-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-07-0 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-bromo- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-08-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-bromo-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-09-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-10-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-chloro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-11-6 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-chloro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-13-8 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-5-nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-14-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-5-nitro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-15-0 CAPLUS

CN 2-Benzofurancarboxamide, 5-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 550999-16-1 CAPLUS

CN 2-Benzofurancarboxamide, 5-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-19-4 CAPLUS

CN 2-Benzofurancarboxamide, 5-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-20-7 CAPLUS

CN 2-Benzofurancarboxamide, 5-amino-N-(3S)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-22-9 CAPLUS

CN 2-Benzofurancarboxamide, 6-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-24-1 CAPLUS

CN 2-Benzofurancarboxamide, 7-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-25-2 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5,7-difluoro-
(CA INDEX NAME)


Absolute stereochemistry.



RN 550999-26-3 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5,7-difluoro-
(CA INDEX NAME)


Absolute stereochemistry.



RN 550999-27-4 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo-5-
fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-28-5 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo-5-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-29-6 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-30-9 CAPLUS

CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-31-0 CAPLUS

CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-32-1 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-fluoro-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-33-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-fluoro- (CA
 INDEX NAME)

Absolute stereochemistry.



RN 550999-34-3 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-fluoro-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-35-4 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-bromo- (CA INDEX NAME)

Absolute stereochemistry. Rotation (+).



RN 550999-36-5 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-bromo-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-38-7 CAPLUS
 CN Naphtho[1,2-b]furan-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-39-8 CAPLUS
 CN Naphtho[1,2-b]furan-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-
 (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-40-1 CAPLUS
 CN Naphtho[1,2-b]furan-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-,
 hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-41-2 CAPLUS
 CN 2-Benzofurancarboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(2-
 cyclopropyl-2-oxoethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-42-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-44-5 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-bromo- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-45-6 CAPLUS

CN Thieno[2,3-f]-1,3-benzodioxole-6-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-46-7 CAPLUS
 CN Thieno[2,3-f]-1,3-benzodioxole-6-carboxamide,
 N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-47-8 CAPLUS
 CN Thieno[2,3-f]-1,3-benzodioxole-6-carboxamide,
 N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-49-0 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-
 nitro- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-50-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-chloro-6-fluoro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-51-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-chloro-6-fluoro- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-52-5 CAPLUS


CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-3-chloro-6-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-53-6 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-fluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-55-8 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-56-9 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-fluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-57-0 CAPLUS
CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-chloro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-58-1 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-3-chloro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-60-5 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 5-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-61-6 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 5-amino-N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 550999-63-8 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-64-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-65-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-66-1 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(trifluoromethyl)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-67-2 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(trifluoromethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-68-3 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 5-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-methyl-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl


RN 550999-70-7 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 5-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-71-8 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 7-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 550999-73-0 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 7-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-74-1 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-chloro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-75-2 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-chloro- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-76-3 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-chloro-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-77-4 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[(2-furanylcarbonyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 550999-78-5 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-[(2-furanylcarbonyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 550999-79-6 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-(benzoylamino)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-81-0 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-82-1 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-83-2 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5-fluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-84-3 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-85-4 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-86-5 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-7-methoxy-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-87-6 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-fluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-88-7 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-fluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-89-8 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-fluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-90-1 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5,7-difluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-91-2 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-5,7-difluoro- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-92-3 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-5,7-difluoro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-93-4 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-94-5 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-methoxy- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-95-6 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-6-methoxy-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 550999-97-8 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-cyano- (CA INDEX NAME)

Absolute stereochemistry.



RN 550999-98-9 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-6-cyano-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 550999-99-0 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-nitro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 551000-00-1 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-4-nitro- (CA INDEX NAME)

Absolute stereochemistry.



RN 551000-01-2 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3S)-1-azabicyclo[2.2.2]oct-3-yl-4-nitro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 551000-02-3 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 6-(acetylamino)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 551000-03-4 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 6-(acetylamino)-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)

Absolute stereochemistry.



RN 551000-04-5 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 4-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 551000-05-6 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, 4-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl- (CA INDEX NAME)


Absolute stereochemistry.



RN 551000-06-7 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, 6-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-chloro-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




●2 HCl

RN 551000-08-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, 6-amino-N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-3-chloro- (CA INDEX NAME)


Absolute stereochemistry.



RN 551000-09-0 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[(1-methylethyl)amino]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl


RN 551000-10-3 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[(1-methylethyl)amino]- (CA INDEX NAME)

Absolute stereochemistry.




RN 551000-12-5 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-cyano- (CA INDEX NAME)

Absolute stereochemistry.



RN 551000-13-6 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-nitro-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 551000-14-7 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-nitro- (CA INDEX NAME)

Absolute stereochemistry.



RN 551000-15-8 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[(methylsulfonyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl

RN 551000-17-0 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[(methylsulfonyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 551000-18-1 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
[bis(phenylsulfonyl)amino]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 551000-19-2 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
[bis(phenylsulfonyl)amino]- (CA INDEX NAME)


Absolute stereochemistry.



RN 551000-20-5 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-
(benzoylamino)-, hydrochloride (1:1) (CA INDEX NAME)


Absolute stereochemistry.



● HCl


RN 551000-21-6 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-(benzoylamino)- (CA INDEX NAME)

Absolute stereochemistry.



RN 551938-28-4 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[(hydroxyamino)iminomethyl]-, hydrochloride (1:2) (CA INDEX NAME)


Absolute stereochemistry.



●2 HCl

RN 551938-29-5 CAPLUS
 CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-6-[(hydroxyamino)iminomethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 551938-30-8 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[(hydroxyamino)iminomethyl]-, hydrochloride (1:2) (CA INDEX NAME)

Absolute stereochemistry.




● 2 HCl

RN 551938-31-9 CAPLUS

CN Benzo[b]thiophene-2-carboxamide, N-(3R)-1-azabicyclo[2.2.2]oct-3-yl-7-[(hydroxyamino)iminomethyl]- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=>